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ABSTRACT 
 Numerous toxins and pathogens gain entry into mammalian cells using cell surface 
glycans. The Iyer group at Georgia State University is working on the development of 
glycoconjugates for the accurate detection of infectious agents. In this thesis, I have focused on 
the development of glycans to detect influenza virus and norovirus. 
 In the first section, I have focused on influenza viruses. A panel of synthetic glycans was 
synthesized as receptor mimics for the specific capture of influenza viruses. The synthetic 
glycans were printed onto commercial glass slides using a free amine at the end of a spacer to 
generate a small focused microarray. This glycan printed microarray was evaluated for its ability 
to capture three strains of influenza viruses. The analytical limit of detection is ~10 pfu/ml, 
(plaque forming units/milliliter) which is clinical relevant as 102 viral particles are typically 
required to cause infection. We also tested the drug susceptibility of current antivirals, Zanamivir 
and Ostelamivir using the microarray and determined the feasibility of this system to determine 
antiviral resistance for different strains. 
 In addition to optical detection, I developed an electrochemical assay to rapidly detect 
influenza viruses. Here, we utilized an unique property of influenza viral surface enzyme, 
Neuraminidase (NA), which cleaves terminal N-Acetyl Neuraminic acid (sialic acid) from cell 
surfaces and proteins. We designed an electrochemical assay that uses glucose bearing sialic acid 
substrates. Glucose is released when exposed to viral NA or intact viruses. The released glucose 
can be detected using repurposed glucose meters. Thus, personal glucose meters that were 
designed to assist diabetics and prediabetics monitor blood glucose can potentially be used to 
detect pathogens. Using this approach, we have detected 19 unique strains of influenza viruses. 
iii 
 
We also demonstrated drug susceptibility using this assay. The limit of detection of this assay is 
102 pfu/sample, which is clinically relevant. The results were validated plaque assays and 
polymerase chain reaction (PCR). 
 In the second part of this thesis, I focused on norovirus detection. I developed a focused 
glycan microarray that comprised of a library of histo blood group antigens (HBGAs). The 
HBGAs were attached to a carrier protein and printed onto activated glass slides. A panel of 
norovirus virus like particles (VLPs) and strains that included different genogroups was exposed 
to the microarray. We found that different VLPs and strains give rise to unique binding patterns. 
When the binding pattern of VLPs for a particular strain were compared to the corresponding 
intact virus, the binding patterns didn't match well, presumably because the virus does not 
recognize the same antibody as the VLPs. Unfortunately, antibodies for the virus cannot be 
generated because the virus cannot be grown in a laboratory setting. Indeed, all norovirus 
samples are obtained from human challenge studies. I also used surface plasmon resonance 
(SPR) studies in an effort to determine the binding affinities. Divalent biotinylated H type 
glycans were synthesized and their binding affinities with different VLPs and viral strains were 
determined. Initial studies suggest that the binding affinities are strain specific. These results 
demonstrate that glycans can be used to capture and isolate norovirus, although more research is 
required to develop glycan based norovirus detection kits. 
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1. Glycan Based Influenza Virus Detection 
 
 
 
 
 
 
 
 
 
 
 
* Most of the work described in this chapter has been published in two publications: 
Zhang, X. ‡; Dinh, H. ‡; Sweeney, J.; Yang, Y.; He, Y.; Dhawane, A.; Iyer, S. S., Glycan based detection 
and drug susceptibility of influenza virus. Anal. Chem., 2014, 86 (16), 8238-8244. (‡ contributed equally 
to the paper) 
Zhang, X.; Dhawane, A. N.; Sweeney, J.; He, Y.; Vasireddi, M.; Iyer, S. S., Electrochemical assay to 
detect influenza viruses and measure drug susceptibility. Angew. Chem. Int. Ed. Engl., 2015, 54 (20), 
5929-5932. 
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1.1 Influenza Virus Introduction 
 Influenza virus is a deadly respiratory virus that is typically spread through contact, 
sneezing and coughing. Seasonal influenza associated illnesses causes 200,000 hospitalizations 
and over 30,000 deaths in the United States every year.1 Emerging strains can be extremely 
virulent, for example, recent emergence of avian H5N1 influenza virus in remote location was 
very concerning as it had a high death rate.2 Most recently, the 2009 H1N1 strain spread rapidly, 
but did not have a high death rate. 3 
 Influenza virus belongs to the family of orthomyxo-viridae viruses. There are three 
serologically distinct types, type A, type B and type C. Type A and type B infects mammals 
where type C viruses does not infect humans.4 Based on the antigenic properties of the virus 
surface protein, further classification is designated as HxNy, where x and y stand for different 
types of surface protein, Hemagglutinin (HA) and Neuraminidase (NA), respectively. In addition 
to H and N, nomenclature includes the year and the location where the virus subtype was isolated. 
For example, A/California/04/2009 (H1N1), represents a H1N1 strain, Type A, isolated in 
California in 2009 with a lineage number 4. HA and NA are essential for the influenza virus life 
cycle, which is described below. 
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Figure 1.1 Influenza virus life cycle and targets for therapeutics. 
First, influenza virus binds to the target cell, second, the virus is endocytosed, 
third, the virus releases the genome and subsequent viral proteins are 
synthesized. Fourth, new viruses are assembled. Fifth, NA cleaves the 
terminal sialic acid to help the viruses exit from host cell.  
Figure is taken from publisher with permission.5 
 
The surface of influenza virus is decorated by three surface proteins: M2 ion channel 
protein, HA, a lectin and NA, which is an enzyme. These proteins play important roles in virus 
life cycle (Figure 1.1). Briefly, the virus life cycle has several steps. 1). Influenza virus bind to 
the target host cell by recognizes its surface glycan (terminal linked N-acetyl Neuraminic acid or 
sialic acid) using virus surface protein HA. The binding process helps the virus gain entry into 
 18 
 
the cell. 2). The virus is endocytosed through a fusion process to allow the virus to enter the host 
cell. 3). The virus releases the genome and subsequently viral protein are synthesized. 4). After 
cRNA (complimentary RNA) synthesis, genome is replicated, new virus is assembled. 5). 
Budding process helps the virus exit the host cell. 6). The enzyme NA cleaves the terminal sialic 
acid residues from the host cell surface. The virion progeny seeks new host cell for subsequent 
infections. 
HA, NA and the M2 channel are essential for viral infection, therefore, HA, NA and M2 
channels have been proposed as potential targets to treat influenza virus infection because of 
their integral role in viral replication.   
Influenza A virus is a negative-sense single stranded RNA virus. The genome is 
composed of eight viral RNA segments which is used to encode 11 major proteins.6 We describe 
the major proteins in the following subsections. 
1.1.1  Hemagglutinin (HA) 
 
Figure 1.2  Hemagglutinin and Neuraminidase. 
a) A view of HA trimer complexed with Neu5Ac. The sialic acid is 
represented as ball and stick model and the proteins are represented as 
 19 
 
ribbons with the space filling model merged into the background. Each part 
of the trimer is represented in three different colors, green, brown and blue. 
b) A view of NA monomer, complexed with Neu5Ac.  
Figure is taken from publisher with permission. 5 
  
 HA is a glycoprotein. HA is formed by three identical subunits (Figure 1.2) and is 
presented as spikes on the lipid membrane of influenza virus. There are two functions of HA, the 
first function is its involvement in binding process,7 HA binds with sialic acid on the surface of 
the host cell to anchor the virus on the surface to help the fusion. The second function is to 
trigger the internalization of  the virus through a fusion process.8  
 There are two subunits HA1 and HA2 formed by HA0 which is a HA precursor. HA1 
contains a binding domain of the HA for sialic acid, while HA0 contains the fusion peptide.9 
These two domains both contribute to the biological functions of HA. Although HA binds with 
sialic acid and sialic acid terminated glycans, the binding affinity is also dependent on the 
linkage between the sialic acid and the penultimate unit, which is typically a galactose unit. Two 
major glycosylation linkages are recognized by HA: an α (2,3) linkage (Figure 1.3) 
predominately in avian and equine viruses, and an α (2,6) linkage found in the human influenza 
viruses.10 Pigs have both α (2, 3) and α (2, 6) linkage, and are often considered as a resource for 
“virus mixing”. A highly pathogenic avian influenza stains, H5N1, that has preference for α (2, 
3) and α (2, 6) linkage has been found recently.11 The reason for increased pathogenicity is that a 
single amino acid mutation in this avian strain, which endows the virus the ability to infect 
human host cells.12 This finding explains that H5N1 avian influenza virus did not infect humans 
when it first emerged, but now possesses that ability. 
 20 
 
 
 
Figure 1.3 α (2,3) linkage and α (2,6) linkage of sialic acid. 
The numbering scheme is represented on the figure as red color. 
  
 Upon binding to the sialic acid unit on the host cell, a receptor-mediated endocytosis 
process helps the virus get into the host cell. The pH (typically 5~6) of the endosome will trigger 
the fusion process, and induce the conformational changes in HA0 to expose the HA2 fusion 
domain. The HA2 is released to the endosomal membrane and helps the endosomal membrane 
contact with the viral.13  
 The low pH (5~6) environment of the endosome is important to induce the HA0 
conformation changing to expose the HA2 fusion peptide. Another biological process is also 
triggered by the low pH environment of the endosome, the M2 ion channel on the surface of the 
virus opens up in low pH environment. This process will acidify the virus core, and help the 
release of the vRNP (viral ribonucleoproteins) from M1, which is the M1 part of the ion channel. 
Consequently, the vRNP is free to enter to the cytoplasm of the host cell.14. 
1.1.2 Neuraminidase (NA) 
 Neuraminidase is another important surface protein of the influenza virus. It plays an 
essential role in the virus life cycle.  NA is a surface protein that made up by four identical 
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subunits. The entire protein is anchored to the viral membrane.15 The NA structure is shown in 
Figure 1.2. On the surface of influenza virus, NA is presented as a tetramer. The shape of NA 
could be described as a mushroom, a head stick on the thin stem. One virus has approximately 
50-100 NAs, as determined by cryo-electron microscopy. 16 
 The biological function of NA is that it catalyzes the cleavage of the terminal sialic acid 
residue. The cleavage mechanism of the terminal sialic acid residue is shown in Figure 1.4. 
There are four steps in the catalytic processes. In the initial step, the carboxylate group changes 
from an axial position to a pseudo equatorial position. Second, the lone pair electron of oxygen 
on the sugar ring triggers the electron transfer to the anomeric carbon, and forms the endocyclic 
sialoyl cation transition state intermediate. Next, tyrosine residue in the active site attacks the 
sialosyl cation. Finally, the lone pair electron from the water molecule attacks the sialosyl cation 
to release Neu5Ac in the glycosylic enzyme intermediate. The major function of NA in the virus 
life cycle is that it can facilitate the virion release from the infected cell by cleaving the sialic 
acid from the host cell.17 Without NA, the emerging virion aggregates on the infected host cell 
and cannot infect more cells. Recently, a mechanism has been proposed based on tyrosinyl-
bound intermediate to explain the resistance of emerging strains to Oseltamivir.18  
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1.1.3  M2 Proton Channel Protein 
 
Figure 1.5 M2 Proton Channel Structure 
a). An ensemble of 15 low energy structure derived from NMR 
restraints. b). A ribbon structure represents the ensemble of part a, 
showing the side chains of His 37 and Trp 41.  
Figure is taken from publisher with permission. 19 
 
 M2 is the third surface protein. It is a single-pass membrane protein and is composed of 
97-residues.19 It forms a tetramer in the native state. The amino termini are directed towards the 
outside of the virus capsid, and carboxyl termini are directed towards inside of the virus capsid.20 
The main biological function of M2 proton channel is that it forms pH-gated proton channels in 
the viral lipid. This proton channel is formed by four transmembrane helices. Based on the 
structure of the M2 channel, the His 37 assists in sensing the pH and the Trp 41 acts as the 
gatekeeper to control the proton flow.21  
 24 
 
 The structure model of the M2 channel has been elucidated based on several technologies 
such as sequence analysis, mutagenesis and solid state NMR.20, 22 The M2 channel is inherently 
unstable and therefore, different analytical methods led to different conclusions in the past. 
However, the construction of residues 18-60 forms a stable tetramer and this helped determine 
the correct structure, which was determined by high-resolution NMR spectra.19 A four helix 
bundle forms the transmembrane helices as shown in Figure 1.5.  
 The structure of the M2 proton channel reveals the biological function. Four 
transmembrane helices pack tightly to each other to form a “gate”. The gate can be closed or 
open depending on the pH of the surroundings as shown in Figure 1.6 because of a 
conformational change of the transmembrane helices. Different pH triggers the conformation 
change of the transmembrane helices. The conformation changes are mainly contributed by Trp 
41, Asp 44 and His 37. The channel gate is formed by indole rings of Trp 41, and stabilized by 
inter subunit hydrogen bonds with Asp 44. Thus, when pH is high, the gate is closed due to the 
interaction between tryptophan and Asp 44. However, at low pH, His 37 is protonated, and the 
imidazole of His 37 destabilizes the transmembrane helix, thus, the interactions between Trp 41 
and Asp 44 is broken and the gate opens.19 Consequently, proton can flow through the M2 proton 
channel across the viral envelop. 
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Figure 1.6 The Activation process of M2 channel 
At high pH, the transmembrane helices are tightly packed, the 
tryptophan gate is closed, at low pH, His 37 inidazoles is protonated, 
this could destabilize the transmembrane helix packing, the gate is 
opened.  
Figure is taken form publisher with permission. 19 
 
1.1.4  Influenza Viral Polymerase 
 The RNA dependent RNA polymerase is encoded by three largest vRNAs. The RNA 
dependent RNA polymerase is mainly composed of three subunits, the acidic subunit PA and the 
basic subunits PB1 and PB2.  There are two biological functions for the influenza virus 
polymerase. First, it helps the viral replication in the host cell by replicating the RNA segment 
and transcribing the gene. Second, it causes the virus mutations through its error prone 
replication due to the lack of proofreading activity. In the viral particle, each ribonucleoprotein 
contains a single polymerase complex, which is consisted of PA, PB1 and PB2. Since the 
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negative sense RNA cannot be directly translated, the pre-existence of the polymerase can 
initiate the first RNA replication and transcription. Once the replication and transcription is 
finished, more polymerase subunits can be synthesized in the cytoplasm, assembled into a trimer, 
and involved in further replication and transcription.23 Biochemical studies show that PA, PB1 
and PB2 interact with each other from the C-terminus to the N-terminus to form an N-terminal to 
C-terminal linear PA-PB1-PB2 arrangement as shown in Figure 1.7. 24 
 There is no proofreading activity from the influenza virus polymerase, leading to an 
influenza virus mutation rate, approximately one error per replicated genome.25 The continual 
mutations of the genome leads to the virus to mutate fast, especially for the M2 protein and NA, 
which are major targets for the antiviral therapy. Therefore, the lack of proofreading activity of 
the viral polymerase is one of the major reasons that make the virus resistant to antiviral drugs 
and help the virus better to adapt to new host species.26 
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Figure 1.7 Features of the polymerase subunits. 
Linear representations of the three polymerase subunits, PA, PB1 and PB2. PA, PB1 
and PB2 interact with each other from C terminus to N terminus. The blue, red and 
green box represent different domain. The X ray crystal structures of the protein 
represent the interaction regions of PA-PB1, and PB1-PB2. 27 
Figure is taken from publisher with permission. 23 
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Figure 1.8 Cap-snatching transcription mechanism of influenza polymerase. 
In transcription, first, PB2 subunit binds with a host pre-mRNA molecule (red), which 
can be cleaved 10-15 nucleotides downstream by the PA endonuclease. The short RNA 
primer is used to initiate polymerization by PB1 subunit using vRNA as the template to 
generate the chimeric viral mRNA (red and blue), which can be used to translate viral 
protein. 
Figure is taken from publisher with permission. 23 
 
  All of three subunits are essential for the transcription and replication process of the 
virus life cycle. The initial step of the transcription process is triggered by cap snatching, in 
which 5’-capped RNA fragments are cleaved from host pre mRNAs. 28 The replication process is 
composed by two steps. First, complementary RNAs (cRNA) are synthesized, and are used as 
replication intermediates to generate more virus ribonucleoprotein, they can also act as templates 
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to the next transcription. Eventually, all of the RNAs are exported from the nucleus to form 
virions at the plasma membrane.29 (Figure 1.8) 
 The function of PA was unclear in the past and several functions were proposed 30 until 
two groups have determined the structure of the N terminal domain of PA 31 which shows that 
the main function of PA subunit is that of an endonuclease.32 There are two subunits labeled as 
N-terminal (25k Da) and C-terminal (55k Da). The C-terminal fragment serves as a binding site 
to PB1 to form the polymerase complex, while the N-terminal subunit contributes to the cleavage 
of the cap peptides from the host pre mRNA.23 
 Previous research demonstrated that the N-terminal of PB1 binds with the C-terminal of 
PA where the short N-terminal of PB1 is co-crystallized as shown in Figure 2.6. At the other end 
of PB1, the interaction of C-terminal with N-terminal of PB2 has been demonstrated.33 The X-
ray structure of the C-terminal fragment of PB1 with N-terminal of PB2 was determined and 
showed that these α helical subunits are tightly folded.27b This interaction interface is highly 
conserved in different avian and human strains, which make this part a possible drug target.23 
The central role in of PB2 is represented in the RNA replication process. It acts as the backbone 
of the polymerase, and holds the catalytic site to help the RNA polymerase complete the 
replication process.34 
 PB2 plays an essential role in the transcription initiation.  It is a major virulence 
determinant of the influenza virus 35 and has been found to affect host range of viruses. 36 It 
binds to the pre mRNAs to generating 5’ capped RNA fragments, which are used as primers for 
the virus transcription.37 Most of PB2 proteins are found in the nucleus of the host cell in 
complex formation with PB1 and PA polymerase subunits. They have been detected in the 
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mitochondria.38 It is proposed that the PB2 in mitochondria can contribute to the preservation of 
mitochondrial function by stabilizing its membrane potential when the host cell is infected by 
influenza virus. However, the function of the PB2 protein in mitochondrial has not been 
elucidated in detail.35 
1.1.5  Antiviral Development Strategies 
 A virus is composed by genetic material (DNA or RNA), functional proteins such 
enzymes and polymerases, and wrapped in a protein coat. Viruses lack a cell wall, ribosomes, 
and other structures, and therefore, they do not respond to antibiotics. The strategies to design an 
antiviral drug are typically to arrest a specific stage of the virus life cycle. The life cycle of viral 
follow a general pattern: 1. Attachment to the host cell. 2. Inject the genome and possibly 
enzyme such as polymerase into the host cell. 3. Replication of the genome by using the host cell 
machinery. 4. Translation of the protein which is essential to grow new viral progeny. 5. 
Assembly all of the components to form the new virus. 6. Release from the host cell to infect 
new targets.  
 One antiviral strategy is to block the interaction of the virus with host cell. The virus 
must attach to the host cell by binding to a specific receptor on the host cell surface. Therefore, 
the method to block the interaction is developing a synthetic protein that blocks the virus from 
interacting with the host cell receptor or developing small molecules to mimic the receptor of the 
host cell. Several antiviral drugs have been developed to fight HIV based on “entry inhibiting” or 
“entry blocking”.39 Amantadine and Rimantadine have been used to combat influenza. 40 
Pleconaril has been used to against rhinoviruses by blocking the virus surface pocket which is 
used to stop the virus uncoating process from releasing its genomic material.41 These approaches 
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have not worked well for influenza thus far, because HA is a lectin; however, some reports that 
target HA have emerged. 42   
 Another approach to design the antiviral drug is to develop nucleotide or nucleoside 
analogous that mimic the building blocks of the RNA or DNA, which deactivates the enzyme 
activity once the antiviral drug stops the replication process. This method has been wildly 
applied to inhibit the reverse transcriptase. The antiviral drug Acyclovir used to against 
herpesvirus is a nucleotide analogue43, and the antiviral drug Zidovudine used to treat HIV 
infection is a nucleotide analogue also.44 Several antiviral drugs have been designed to target the 
translation process. Antisense drugs and ribozymes are developed based on this strategy.45 The 
last step of virus in the life cycle is the release process form the host cell. Two antiviral drugs 
name Zanamivir and Oseltamivir have been developed to treat influenza virus infection by 
inhibiting the NA on the virus surface to prevent the release of viral progeny.23, 25-26  
1.1.6 Development of Antivirals for influenza 
 There are five licensed influenza antivirals approved by FDA in the United States. Three 
of them are NA inhibitors, which can inhibit NA to prevent the new virus release process. They 
are Oseltamivir (Tamiflu®), Zanamivir (Relenza®) and Peramivir (Rapivab®). All of them have 
activity against influenza A and B viruses. Amantadine and rimantadine are used as antiviral 
drugs as they are active against influenza A virus by inhibiting M2 channel, however, most 
circulating strains are resistant to amantadine and rimantadine. 
1.1.6.1 M2 Inhibitors 
 As mentioned previously, M2 proton channel is essential for the virus life cycle. It 
equilibrates pH across the viral membrane during the virus entry into the host cell and the trans-
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Golgi membrane of the host cell during viral maturation.46 Adamantane is the first synthetic 
compound that was shown to inhibit influenza virus replication process.47 Two adamantane 
derivatives, amantadine and rimantadine,(Figure 1.9) have been developed as licensed antiviral 
drugs for influenza infection treatment and they are trademarked as Symmetrel® and 
Flumadine®, These two antiviral drugs were used as the first effective licensed antiviral drugs 
against outbreak of influenza A drugs in past decades.46 However, in recent flu seasons, both of 
them showed a high level of resistance to influenza A (H3N2) and influenza A (H1N1). 
Therefore, they are no longer recommended for antiviral treatment or chemoprophylaxis in the 
2015-2016 influenza seasons.  
NH2
Adamantane Rimantadine Amantadine
NH2
 
Figure 1.9 Structure of Adamantane, Rimantadine and Amantadine 
 
1.1.6.2  NA Inhibitors  
 The first NA inhibitor was developed in 1966,48 and at that time the catalytic mechanism 
of the NA was still unclear. In early 1990s, the crystal structure of the influenza virus surface 
proteins was determined and the active site of the NA was discovered, which provided more 
structural details and strategies to design new and specific NA inhibitors. 49 The mechanism of 
NA has been discussed in section 1 and shown in figure 1.4. 
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 Four NA inhibitor antiviral drugs have been developed, two of them are FDA approved, 
Zanamivir and Oseltamivir. Peramivir is approved for use in South Korea and Japan, while 
Laninamivir is approved for use in Japan.50 The structures of these four NA inhibitors are shown 
in Figure 1.10. 
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Figure 1.10.  Structures of NA inhibitors. 
1.1.7 Influenza Virus Detection 
In addition to antiviral strategies and vaccines, early diagnosis can help arrest spread of 
influenza virus. There is a critical need for rapid detection method of influenza virus. Current 
detection methods are inadequate. A comparison of different tests based on the ASSURED 
(Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free and 
Deliverable to end-users) criteria set forth by the World Health Organization (WHO), is given in 
Table 1.1. Briefly, there are four major detection methods: rRT-PCR (real time Reverse 
Transcription Polymerase Chain Reaction), virus culture, antibody based test, and fluoro/ 
colorimetric test. rRT-PCR detection is expensive and require sophisticated instruments, trained 
personnel and the right primers. 51 In addition, testing multiple samples takes time and it is not 
possible to apply this detection method in resource-poor areas. Although large hospitals can 
afford sophisticated multiplexed PCR systems, multiple testing takes time, effort and money. 
Virus culture takes days and is expensive to test hundreds of samples. Fluorescence tests require 
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a laboratory setting. 52 Antibody tests are rapid and use friendly, but are not sensitive and 
antibodies suffer from stability and quality control issues. 53 The CDC does not recommend 
using antibody based tests because they are not sensitive. Additionally, drug susceptibility cannot 
be determined using antibody based tests. 
 
ASSURED 
Criteria 
Detection methods 
Culture Nucleic Acid Fluoro/ Colorimetric Antibody 
Affordable 
No, requires 
laboratory 
equipment 
No, Cepheid and 
Biomeriux sell 
point of care 
system, but cost 
thousands of 
dollars. 
No, an 
instrument costs 
thousands and 
the reagents are 
expensive. 
Yes, but cost varies. 
Typical cost is ~ 18-20 
$ per test. e.g. Quidel 
Flu A&B test is 450 $ 
for a pack of 25. 
However, the cost of 
these tests is coming 
lower. 
Sensitive High High High 
No, very low 
sensitivity (20-80%), 
especially at low 
concentrations. 54 
Selective 
High, can 
distinguish 
between live 
and dead 
virus. 
High, but requires 
the correct primers 
and cannot 
distinguish 
between dead and 
live virus 
Medium/High 
but cannot 
distinguish 
between live 
and dead 
viruses. 
High, > 90%, but 
cannot distinguish 
between live and dead 
virus. 
Rapid No, requires days. 
No, sample 
preparation takes 
hours, but newer 
systems are 
integrated to yield 
results in 1-2 
hours. 
60 minutes. 15 minutes 
Robust 
No, requires 
several 
reagents, 
which are not 
stable 
Yes/No, some 
reagents may 
require 
refrigeration 
No, requires 
refrigeration. 
Yes/No, depends on 
antibody stability. May 
require refrigeration 
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User friendly 
No, requires 
trained 
personnel. 
Yes/No, newer 
systems are 
becoming simpler, 
but still require 
trained personnel. 
No, requires 
trained 
personnel. 
Yes 
Equipment free No No No Yes 
Deliverable to 
end users 
No, requires a 
laboratory. No, requires space
No, requires 
space 
Yes, small footprint, 
portable 
Drug 
susceptibility 
Yes, but takes 
days 
Yes, but takes 
days 
Yes, but 
requires hours No 
Table 1.1  A comparison of different tests for influenza virus based on the ASSURED 
  Clearly, there is a great need to develop new diagnostics for influenza viruses. We have 
been developing receptor (sialic acid) mimics as novel recognition molecules to capture 
influenza viruses. These efforts are described below. 
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1.2 Glycan Based Detection and Drug Susceptibility of Influenza Virus Using 
Microarray 
 
 
 
 
 
 
 
 
 
 
 
 
 
 This part of the thesis has been published (Xiaohu Zhang, et al. "Glycan based detection 
and drug susceptibility of influenza virus." Analytical chemistry. 86.16. 2014, 8238-8244.)  
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1.2.2 Introduction 
 Our first approach was to develop a highly focused glycan microarray to capture and 
detect influenza viruses. Since printing the glycans to generate a microarray is part of the project, 
we describe the fabrication of glycan microarrays in the next section. This will be followed by 
the design and synthesis of NA specific glycans, followed by biological evaluation.  
1.2.3 Glycan microarray 
 The surface of living cell is decorated with highly diverse structures of glycans, these 
glycans are involved in many biological process by recognizing the glycan binding proteins. 
Glycan microarray has been introduced since 2002 to detect the binding pattern for this class of 
biological molecules.55 Glycan microarray was successfully developed based on the printed 
arrays of other biomolecules such as DNA arrays.56 It filled a critical need for the biological 
molecular recognition detection with the synthetic glycan libraries. The glycan libraries could be 
high throughput screened by different glycan binding proteins to identify their biological roles. 
Publications based on glycan microarray have grown exponentially since the glycan microarray 
is introduced to detect the binding pattern of the glycans. It is widely used in the research area 
including functional glycomics, diagnosis and drug discovery. 
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Figure 1.12 Glycan Microarrays 
Glycan microarrays can be generated by different strategies and the binding pattern of pathogens 
or antibody will be evaluated by fluorescent intensity.  
Figure is taken from publisher with permission. 57  
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 The printed glycan microarray detection method is shown in Figure 1.12. First,  glycans 
are prepared to printed on the surface of the slide, thus, the glycan could be anchored on the 
surface of the slide, second, unmodified area of the slide will be covered by other molecular such 
as PEG to avoid the detection signal noise. Next, analyte such as glycan recognition protein or 
pathogens are incubated with the array of glycans and the unspecific binding will be washed 
away.  If the analyte had a fluorescent tag, the slide will be scanned on a microarray scanner and 
further analyzed by special image software, if not, another molecule such as fluorescent tag 
marked antibody will be introduced to incubate with the array. Finally, the image of the 
microarray will be analyzed to generate the binding pattern of the analyte. Glycan microarray has 
been widely used in binding pattern test as shown in Figure 1.13. 
Figure 1.13 Applications of glycan microarray 
Glycan microarray has been widely used to test the binding pattern of 
carbohydrates with enzymes, antibodies, cells or pathogens and inhibitors. 
Figure is taken from publisher with permission. 57 
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  Common strategies to generate glycan libraries are mainly based on three methods: 
synthetic, enzymatic, and naturally derived glycans as shown in Figure 1.14. The synthetic and 
enzymatic methods have been widely used to generate the large number of the glycan libraries. 
Unfortunately, although great strides have been made to develop more convenient methods for 
the synthesis of glycans in the last 30 years, 58 unlike DNA and protein synthesis, there are no 
systematic ways for routine synthesis of glycans. Complicated glycans are still hard to obtain 
from synthetic and enzymatic methods. Releasing from glycoproteins and glycolipids is another 
major method to obtain glycans for array constructions. However, the major challenge to set up 
glycan libraries from natural sources is the purification of individual glycans and their structure 
verification. 
 
Figure 1.14 Three methods to generate glycan libraries 
Synthetic method, glycan is synthesized by different method using PG (protection groups), L 
(linker) is introduced at the terminal of glycan. Enzymatic method, glycan is obtained by 
enzymatic catalytic reaction. Naturally derived method, glycan is cleaved and isolated from 
naturally product such glycolipid or glycoprotein. 
Figure is taken from publisher with permission. 59 
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 To anchor the glycans on the surface of the array slide, the glycan need to be modified 
with a functional linker. Several strategies have been applied to modify the glycan including 
reductive amination60, glycosylamine formation and trapping61, hydrazide chemistry62, oxyamine 
and N-alkyl oxyamine condensations63 as shown in Figure 1.15. 
 
Figure 1.15 Strategies applied to modify the glycan libraries. 
Briefly, several strategies have been applied to modify the glycan such as reductive 
amination, glycosylamine formation, hydrazide chemistry, oxyamine and N- alkyl 
oxyamine condensations. The aim of the modification is to introduce the linker to 
the glycan. 
Figure is taken from publisher with permission. 59 
 
 To finally anchor glycan on the surface of the array slide, the solid surface needs to be 
modified to introduce the spacer of the glycan. Strategies used to modify the slide surface 
include the methods that have been used to prepare DNA and protein microarrays, and the novel 
methods that developed specifically for glycan microarrays. The modification of the surface will 
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be finally used to immobilize or fabricate the glycan on to it. The modification methods are 
shown in Figure 1.16. 
We have used two different methods to fabricate glycan microarrays. For influenza 
detection, we have attached the linker to the glycans. The linkers are terminated with an amine, 
which is printed on activated carboxylic acid slides. For norovirus detection, we have glycans 
attached to BSA, which is printed onto glass slides. The two different strategies and the 
biological evaluation are described in the following sections.  
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Figure 1.16 Methods to modify the surface of the array slide 
Based on different linker of the glycans, different methods are applied to immobilize glycans on the 
surface of microarray chips. Function groups show on the surface of the chips and the 
corresponding glycans are shown on the top of the chips. 
Figure is taken from publisher with permission. 59 
 
 45 
 
1.2.4 Design and Synthesis 
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Figure 1.17 Structures of the tailored glycans. 
 The blue ellipse represents the two glycan headgroups, and I and II represent mono and bivalent 
derivatives. The natural receptor, N-acetyl neuraminic acid (sialic acid), and the FDA approved antivirals, 
Zanamivir and Oseltamivir, are also shown. 
 
 The structures of the eight molecules used to develop the focused microarray are shown 
in Figure 1.17. There are several salient features of the designer molecules. First, all eight 
molecules are derived from the natural receptor, namely sialic acid. Second, the molecules have 
a free amine at the end of a spacer which is necessary for facile attachment to an activated 
carboxyl acid group on any surface. Third, the molecules also have an amine or a guanidine 
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group at the four position; introduction of a polar group at the four position has been 
demonstrated to be highly specific to influenza virus as X-ray structures have shown that the 
polar group fits very well into a binding pocket of influenza virus NA, but doesn’t fit well into 
human or bacterial NA. 64 Fourth, we designed two types of molecules;  SC1-4 are sialic acid 
analogues that have spacers attached to the 2 position via a thiol linkage, in contrast, SC5-8 are 
analogues derived from Zanamivir® and attached to the spacer at the 7 position. 65 Finally, since 
we recently demonstrated that molecules similar to SC1-4 and bivalent molecules thereof, 
inhibited two H1N1 and H3N2 strains at low nanomolar concentrations, we designed 
monovalent and bivalent derivatives.65c The bivalent derivatives were synthesized for two 
reasons. First, the bivalent scaffold provides additional distance from the microarray surface for 
the NA’s of the virus to bind.  Second, NA exists as a tetramer with four binding sites, the 
distances between the two glycan headgroups are spaced such that a single molecule could fit 
into to two binding sites from a single NA tetramer or alternatively, fit into the pockets of two 
adjacent NA tetramers on a single virion. 66 When these mono and bivalent molecules are 
tethered to a surface, the overall binding affinity of multiple glycans with influenza viruses is 
expected to increase exponentially, leading to a higher capturing efficiency.  
The syntheses of the molecules are shown in Scheme 1.1 and 1.2. For SC1-4, the 
thioacetate group of the known azido compound 1 was reacted with a suitable six carbon spacer, 
which had a chloride at the terminus to yield 2 in appreciable amounts. The azide was reduced 
under mild conditions using triphenylphosphine and the amine group was either protected by a 
tert-butoxy group or a suitably protected guanidine group followed by replacement of the 
chloride by an azide using sodium azide to yield 3a and 3b in decent yields. Zemplén 
deprotection to remove the acetates and methyl ester was followed by acidic removal of the tert-
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butoxy groups and subsequent reduction of the azide using standard hydrogenation conditions 
yielded the monovalent compounds SC1 and SC2 which had an amine and a guanidine group at 
the four position of the sialic acid, respectively. Copper(I) catalyzed 1,3 dipolar addition of 3a,b 
with a dimeric scaffold, 4 bearing two alkyne groups resulted in the fully protected bivalent 
compounds, 5a,b in good yields. The protecting groups were removed using the same conditions 
as described for the monovalent derivatives to yield the bivalent compounds, SC3-4. For the 
Zanamivir analogues, SC5-8, we attached the spacer to the seven hydroxyl group as 
modifications at this position are well tolerated by NA, indeed this approach has been used to 
attach a biotin to Zanamivir. To this end, we elaborated the known azido compound 6 by 
reducing the azide and protecting the free amine group using a tert-butoxy group to yield 7 in 
high yields. This was followed by base induced deprotection of the acetate groups and acetonide 
protection of the 8, 9 hydroxyl groups leaving the hydroxyl group at the 7 position open for 
conjugation to the spacer. The terminal amine of a six carbon spacer bearing an azide group at 
the opposite end was conjugated to 8, in a two-step procedure using p-nitrochloroformate as the 
coupler to yield the carbamate 9. The acetonide group was removed under mild acidic conditions 
to produce 10a. The guanidine derivative, 10b was synthesized from 10a, the tert butoxy group 
was removed and a suitably protected guanidine group was attached to the free amine to yield 
10b in significant amounts. This strategy of installing the guanidine group at this later stage was 
more successful in our hands as opposed to introducing the guanidine group early in the 
synthesis, the latter strategy gave us undesirable products and variable results. Global 
deprotection of 10a, b was performed as described for SC1,2 to yield SC5,6 in good yields. The 
bivalent derivatives SC7,8 were synthesized from 10 a,b in a manner similar to the synthesis of 
SC3,4 by coupling to the scaffold 4, followed by global deprotection. The final compounds were 
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purified using size exclusion chromatography using Biogel P2 and the appropriate fractions 
containing the compounds were freeze dried to produce colorless foamy solid material. 
   
 
Scheme 1.1 Synthesis route for SC1, SC2, SC3 and SC4. 
 (a) 6-Chlorohexyl 4-methylbenzenesulfonate, DEA, DMF, rt, 4 h. 80% (b) i. PPh3, THF/H2O (1:1), 
40 °C, 12 h. ii. (t-Boc)2O, TEA, THF, 60%. iii. NaN3, DMF, 60 °C. 90%. (c) i. PPh3, THF/H2O (1:1), 
40 °C, 12 h. ii. 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea, TEA, HgCl2, 85%. iii. NaN3, 
DMF, 60 °C. 93%. (d) Na-L-ascorbate, CuSO4, THF/H2O. 12 h, 60% for 5a; 65% for 5b. (e) i. NaOMe, 
MeOH. ii. DCM/TFA. iii. NaOH, MeOH, 80% yield for SC3, 70% yield for SC4. (f) H2, Lindlar catalyst, 
EtOH/H2O, 4 h, 75% yield for SC1, 70% yield for SC2. 
 49 
 
O
N3
COOMe
AcHN
AcO
AcO
OAc
1.81.6
a,b
1.9
c,d
1.7
e
f
O
NHBoc
COOMe
AcHN
AcO
AcO
OAc
O
NHBoc
COOMe
AcHN
O
O
OH
O
NHBoc
COOMe
AcHN
O
O O
O
N
H
N3
O
R
COOMe
AcHN
R1
R1 OO NH
O
NH
H
N
O
NHBoc
SC5: R = NH2
SC6: R = NHC(=NH)NH2
1.10a: R = NHBoc, R1=
1.10b: R = NHC(=NBoc)NHBoc, R1= OH
SC7: R = NH2
SC8: R = NHC(=NH)NH2
O
NH
O
NH
NN
N
NH
NHBoc
O
NNN
1.4
O
N
H
NH2
O
R
COOH
AcHN
HO
HO O
O
N
H
O
R
COOMe
AcHN
R1
R1 O
O
N
H
O
R
COOMe
AcHN
R1
R1 O
O
NH
O
NH
NN
N
NH
NH2
O
NNN
O
N
H
O
R
COOH
AcHN
HO
HO O
O
N
H
O
R
COOH
AcHN
HO
HO O
j,g,k
i
j,g
OO NO2
O
O
1.11a: R = NHBoc, R1=
1.11b: R = NHC(=NBoc)NHBoc, R1= OH
O
O
g,h
 
Scheme 1.2 Synthesis route for SC5, SC6, SC7 and SC8. 
(a) H2, Lindlar catalyst, EtOH, 4 h, quant. (b) Boc2O, TEA, THF, 12 h, 86%. (c) NaOMe, MeOH, 1 h, 
quant. (d) H+ resin, acetone, 12 h, 88%. (e) DMAP, pyridine, p-NO2C6H4OCOCl, 12 h, 80%. (f) 6-Azido-
hex-1-amine, CH3CN, TEA, 3 h, 89%. (g) TFA, DCM. (h) 1,3-Bis(tert-butoxycarbonyl)- 2-methyl-2-
thiopseudourea. HgCl2, TEA, DCM, 12 h, 84%. (i) Na-L-ascorbate, CuSO4, THF/H2O, 12 h. 78% for 11a; 
80% for 11b. (j) NaOH, MeOH. 1 h. 70% for SC7; 79% for SC8. (k) H2, Lindlar catalyst, EtOH, 4 h. 76% 
for SC5; 72% for SC6. 
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 The synthetic glycans were printed onto commercial glass slides bearing activated 
carboxyl groups for conjugation to the free amines of SC1-8 to produce a focused microarray. 
Printing was performed at various concentrations; we used a concentration of 200 μM for all 
assays in this report as it gave us excellent signal to noise ratio. Amine terminated PEG was 
printed as a negative control. Amine terminated biotin was included as a positive control.  The 
microarray was exposed to three different strains of influenza virus, two H1N1, 
A/Brisbane/59/2007 and A/Solomon Islands/3/2006 and a H3N2, A/Aichi/2/1968. The strains 
were incubated at rt for 60 min, followed by incubation of the appropriate primary and 
fluorescently labeled secondary antibody. The slides were washed at every stage extensively and 
the slides were scanned using a Genepix scanner at 532 or 635 nm. Reproduced in Figure 1.18 is 
the fluorescence image where the microarray was exposed to 105 PFU of H1N1 Influenza viruses 
A/Brisbane/59/2007.  The image clearly shows that the bivalent compounds, SC3,4,7,8 captured 
the virus very well, however, most of the monovalent compounds, SC1,2,5,6 bind weakly to this 
strain, suggesting that the bivalent derivatives provide the required distance from the surface for 
the virus to bind. We and others have observed this phenomenon before, binding of glycans to 
their respective analytes are highly dependent on glycan density and presentation. Exposure to 
H3N2 strain A/Aichi/2/1968, resulted in similar results (Figure 1.19-1.21), however, all 
compounds bound well to H1N1, A/Solomon Islands/3/2006, indicating that this virus strain is 
more accommodating in its binding preferences. (Figure 1.19-1.21). Non-specific binding to the 
control ligand, PEG, was negligible, which is a very important aspect of biosensor development 
as viruses are notorious in terms of non-specific binding. Several other controls (with buffer only, 
using other synthetic glycans) were performed and all of these control experiments resulted in no 
binding.  We observed a differential response to the ligands for each viral strain, for example, the 
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A/Aichi/2/1968 strain exhibits similar binding to all four bivalent compounds, the 
A/Brisbane/59/2007 strain binds better to the bivalent compounds, SC4 and SC8, with the 
guanidine group at the four position, with the best binder being SC4. With more ligands and 
slight differences in the binding affinities, this differential pattern could potentially be used to 
develop a “fingerprint” pattern of recognition for each strain, including emerging strains. 67 
 Next, we determined the analytical limit of detection using different concentrations of the 
different strains from 106 to 101PFU. As shown in Figure 1.19-1.21, the bivalent compounds 
bind to the three different strains at higher concentrations very well with high relative 
fluorescence intensities.  At the lowest tested concentration of 101 PFU, the bivalent compounds 
SC3 and SC7 bind well to the H1N1 A/Brisbane/59/2007 and the A/Solomon Islands/3/2006 
strains, however, only SC3 binds to the H3N2 A/Aichi/2/1968 strain. Known differences in the 
binding pockets of N1 and N2 could be a possible reason for this difference in binding at lower 
concentrations in addition to the number of NAs present on the surface of each strain. 68 We note 
that these first generation ligands can capture extremely low clinically relevant concentrations of 
viruses and further optimization could lead to lower limits of detection. Finally, we tested the 
microarray for susceptibility to FDA approved antivirals, Zanamivir® and Oseltamivir® (Figure 
1.22-1.24). Briefly, known concentrations of the three strains were premixed with either one of 
the antivirals and exposed to the microarray. Washing to remove unbound virus was followed by 
detection using the appropriate primary and labeled secondary antibody. It was gratifying to 
observe no binding to any of the compounds for all three strains, which indicates that the 
antiviral blocks the NA leading to loss of signal. There are two outliers, SC3 and SC7. In the 
presence of antivirals, SC3 binds H3N2 A/Aichi/2/1968 strain and SC7 binds both H1N1 strains. 
A possible explanation for these observations could be that the binding pocket of HA for each 
  
particular
to the stru
Figure 1.
for Figure
sera to i
polyclona
A/Solomo
performed
 
 strain coul
cture of the
Figure 1
19-1.21, fluo
 1.18. Fluore
nfluenza A/ 
l antiserum 
n Islands/3/2
 in triplicate
d accommo
 glycan hea
.19 Limit of
rescence inte
scence inten
Solomon Is
chicken to A
006 was scan
. 
date sialic a
d groups in 
 detection fo
nsity for A/B
sity was mea
lands/3/2006
/Aichi/2/19
ned at 532 n
cid with an 
SC3 and SC
r H1N1 Inf
risbane/59/2
sured by the 
 (H1N1) an
68 (H3N2) 
m and A/Aic
amine at the
7. 
luenza A/Br
007 was me
Genepix sca
d antiferret 
and Alexa F
hi/2/1968 at
 4 position,
isbane/59/2
asured as pre
nner using fe
rhodamine 
luor 633 lab
 635 nm. All
 which is si
 
007. 
viously desc
rret hyperim
labeled anti
eled antichi
 experiments
53 
milar 
ribed 
mune 
body; 
cken. 
 were 
  
 
 
Figure 1.20
Figure
 Limit of de
 1.21 Limit
tection for H
 of detection
1N1 Influen
 for H3N2 I
za A/Solom
nfluenza A/
on Islands/
Aichi/2/196
 
3/2006. 
 
8. 
54 
  
F
Figure 1.2
105 PFU f
as previou
 
igure 1.22 D
2-1.24, ten n
or 30 min at 
sly described
rug suscep
anograms of 
rt and subseq
 in Figures 1
tibility studi
antivirals Za
uently added
.18. All expe
es for H1N
namivir or O
 to the micro
riments were
1 Influenza A
seltamivir w
array. Fluore
 performed in
/Brisbane/
ere premixed
scence inten
 triplicate. 
 
59/2007. 
 with the stra
sity was mea
 
55 
ins at 
sured 
  
Figu
 
 
           
1.2.5 C
 W
the abilit
We deter
relevant. 
FDA app
strains an
within ho
resistanc
re 1.23 Dru
Figure 1.2
onclusion 
e have syn
y of a focus
mined the l
We also de
roved antiv
d performin
urs using m
e is typicall
g susceptibi
4 Drug susc
thesized tail
ed microarr
imit of dete
monstrated 
irals, Zanam
g the assay.
inimal tools
y performe
lity studies 
eptibility stu
ored glycan
ay to captur
ction to be 
that the ass
ivir® and 
 Thus, the a
. In contras
d in a clini
for H1N1 In
dies for H3
s, printed th
e three influ
101 PFU, wh
ay can be u
Oseltamivir
ssay reporte
t, current ge
cal laborato
fluenza A/S
N2 Influenz
em onto gl
enza strain
ich indicate
sed to test d
®, by prem
d in this arti
notyping m
ry using m
olomon Isla
a A/Aichi/2
ass slides a
s at differen
s that the a
rug suscept
ixing the an
cle can be p
ethods to de
olecular ma
nds/3/2006.
 
/1968. 
nd demonst
t concentrat
ssay is clini
ibility of cu
tivirals wit
erformed ra
termine ant
rkers by tr
56 
 
rated 
ions. 
cally 
rrent 
h the 
pidly 
iviral 
ained 
 57 
 
personnel, specialized equipment and days to accomplish. We are currently expanding our efforts 
to develop second generation ligands and include more strains to demonstrate broad applicability. 
By further optimization of ligand structure, testing different conditions and biosensor platforms, 
this assay has the potential to be translated to rapid diagnostic tests.  
1.2.6 Experiment Section 
1.2.6.1 General Information 
 All reagents and solvents were of reagent grade or were purified by standard methods 
before use. Column chromatography was carried out on flash silica gel (Sorbent 230–400 mesh). 
TLC analysis was conducted on silica gel plates (Sorbent Silica G UV254). NMR spectra were 
recorded at 1H (400 MHz) and 13C (100 MHz) on a Bruker instrument. Chemical shifts and 
coupling constants (J values) are given in ppm and hertz, respectively, using solvents (1H NMR, 
13C NMR) as the internal standard.  All reactions were performed under argon atmosphere using 
degassed solvents. 
1.2.6.2 Abbreviation 
 N,N-Dimethyl formamide, DMF; Ethyl acetate, EtOAc; Trifluroacetic acid, TFA; 
Acetonitrile, CH3CN; Azidotrimethylsilane, TMSN3; Diethylamine, DEA; 
Trimethylsilyltrifluoromethanesulfonate, TMSOTf; p-Toluene sulfonyl, Tos; Di-tert-butyl 
dicarbonate, (Boc)2O; tert-Butyl alcohol, t-BuOH; Methanesulfonyl chloride, MsCl; Methanol, 
MeOH; Tetrahydrofuran, THF; Dichloromethane, DCM; Hydrochloric acid, HCl; 
Triphenylphosphine, PPh3; Sodium sulfate, Na2SO4; Sodium azide, NaN3; N-methyl morpholine, 
NMM; 2-Chloro-4,6-DiMethoxy-1,3,5-Triazine, CDMT; Sodium methoxide, NaOMe; Cupric 
sulfate, CuSO4; Triethylamine, Et3N; De-ionized water, DI water; Hydrogen gas, H2; , H2O; 
 58 
 
Triethylamine, Et3N; Mercury(II) chloride, HgCl2; Dimethylamino pyridine, DMAP; Sodium 
bicarbonate, NaHCO3; Acetonitrile, CH3CN. 
1.2.6.3 Synthesis and Characterization 
Compound 2: 6-S-[Methyl 5-acetamido-7, 8, 9-tri-O- acetyl-4-azido-3, 4, 5-trideoxy -D- 
glycero-α-D-galacto-non-2-ulopyranosyl) onate]-1-chloro-hexane.  
 
 To a stirring solution of compound 166 (0.50 g, 0.94 mmol) in DMF (1.0 ml), DEA (0.95 
ml, 9.4 mmol) was added.  The reaction mixture was stirred for 10 min at rt. 6-Chlorohexyl 4-
methylbenzenesulfonate (0.35 g, 1.1 mmol) was added and the reaction stirred for additional 12 
h. The reaction mixture was quenched using brine solution (0.20 L, 1x) and extracted with ethyl 
acetate (0.050 L, 3x).  Organic layers were combined and washed with HCl solution (0.05 ml, 
1M, 1X), dried over Na2SO4 and concentrated in vacuo. The title compound was purified using 
column chromatography with hexane:acetone (3:1) as eluent to yield a yellow oil (0.46 mg, 80% 
yield).  1H NMR (400 MHz, CDCl3) δ  5.57 (d, J = 8 Hz, 1H), 5.39-5.36 (m, 1H), 5.31 (d, J = 7.6 
Hz, 1H), 4.34-4.30 (m, 1H), 4.25-4.19 (m, 1H), 4.11 (d, J = 10.8 Hz, 1H), 4.06-4.02 (m, 1H), 
3.83 (s, 3H), 3.56 (vt, J = 6.4, 13.2 Hz, 2H), 3.33-3.25 (m, 1H), 2.82-2.73 (m, 2H), 2.59-2.53 (m, 
1H), 2.18 (d, J = 3.2 Hz, 6H), 2.06 (s, 3H), 2.01 (s, 3H), 1.81-1.73 (m, 3H), 1.55-1.39 (m, 6H).  
13C-NMR (100 MHz, CDCl3) δ 170.8, 170.7, 170.6, 170.0, 168.3, 82.9, 72.8, 68.3, 68.0, 62.0, 
58.0, 52.3, 45.0, 38.2, 32.4, 29.1, 28.7, 28.0, 26.3, 23.4, 21.1, 21.0, 20.7.  HRMS (ESI):  
Calculated for: C24H37ClN4O10SH, 608.1919; found, 609.1975 (M+H). 
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Compound 3a: 6-S-[Methyl 5-acetamido-7, 8, 9-tri-O- acetyl-3, 4, 5-trideoxy -4-(N-tert-
butyloxycarbonyl)-amino-D-glycero-α-D-galacto-non-2-ulopyranosyl)onate]-1-azido-
hexane. 
 
 To a stirring solution of compound 2 (0.20 g, 0.33 mmol) in a mixture of THF: H2O (5.0 
ml, 1:1), PPh3 (0.10 g, 0.39 mmol) was added and the reaction was heated at 40 °C for 12 h. The 
solvent was removed in vacuo and the residue purified by column chromatography to obtain a 
clear oil. This compound was directly taken to the next step without further purification. To a 
stirring solution of the crude product (0.18 g, 0.31 mmol) in THF (0.010 L) and TEA (31 mg, 
0.31 mmol), di-t-butyl carbonate anhydride (0.10 g, 0.47 mmol) was added. Reaction mixture 
was stirred for 12h at rt. The white solid was filtered and the residue was concentrated, dissolved 
in DCM (25 ml) and washed with HCl (25 ml, 1M, 1x). The organic layer was dried over 
Na2SO4 and concentrated in vacuo. Product was purified via column chromatography with 
hexane: acetone (5:1) to yield clear yellow oil (0.13 g, 60% yield for two steps). 1H NMR (400 
MHz, CDCl3) δ 5.46 (s, 1H), 5.33 (s, 2H), 4.75 (d, J = 8.8 Hz, 1H), 4.28 (d, J = 12 Hz, 1H), 4.09 
(d, J = 8.8 Hz, 1H), 3.88 (d, J = 10.4 Hz, 1H), 3.79-3.73 (m, 5H), 3.52 (t, J = 6.4, 3H), 2.72 (d, J 
= 11.6 Hz, 2H), 2.54-2.48 (m, 1H), 2.15 (s, 3H), 2.11 (s, 3H), S-4 2.03 (s, 3H), 1.88 (s, 4H), 
1.77-1.71 (m, 4H), 1.38 (s, 19H). 13CNMR (100 MHz, CDCl3) δ 171.0, 170.7, 170.0 169.9, 168.7, 
156.0, 83.4, 80.0, 68.5, 67.5, 62.2, 52.9, 50.2, 50.0, 45.0, 39.2, 32.4, 29.1, 28.7, 28.3, 26.4, 23.2, 
21.2, 20.8, 20.7. HRMS (ESI): Calculated for C29H47ClN2O12S: 682.2538; Found: 683.2613 
(M+H). 
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 To a stirring solution of the chloro derivative (71 mg, 0.10 mmol) in DMF (1.0 ml) NaN3 
(65 mg, 1.04 mmol) was added and the reaction was stirred at 60 °C. After 12 hr, the reaction 
mixture was quenched with DI water (25 ml) and extracted with DCM (25 ml, 3x). The organic 
layers were combined, washed with brine (25 ml, 1x), dried over Na2SO4 and concentrated in 
vacuo, to yield a clear oil (64 mg, 90% yield). 1H NMR (400 MHz, CDCl3) δ 5.47 (d, J = 12 Hz, 
1H), 5.33 (s, 2H), 4.75 (d, J = 8 Hz, 1H), 4.29 (d, J = 12 Hz, 1H), 4.09 (d, J = 8 Hz, 1H), 3.87 (m, 
1H), 3.79 (s, 3H), 3.60 (m, 1H), 3.52 (vt, J = 12, 8.0 Hz, 2H), 2.73 (d, J = 12 Hz, 2H), 2.54-2.48 
(m, 1H), 2.15 (s, 3H), 2.11 (s, 3H), 2.03 (s, 3H), 1.88 (s, 3H), 1.77-1.74 (m, 3H), 1.5-1.40 (m, 
2H), 1.38 (s, 14H). 13C NMR (100 MHz, CDCl3) δ 171.0, 170.7, 170.1, 170.0, 168.7, 156.0, 83.4, 
80.0, 68.5, 67.4, 62.2, 52.9, 50.2, 50.0, 45.0 39.2, 32.4, 28.3, 26.4, 23.2, 21.2, 20.84, 20.80. 
HRMS (ESI): Calculated for C29H47N5O12S: 689.2942; Found: 690.3004 (M+H). 
Compound 3b: 6-S-[Methyl 5-acetamido-7, 8, 9-tri-O- acetyl-3, 4, 5-trideoxy-4-(bis-N, N'-
tert-butyloxycarbonyl)-guanidino-D-glycero-α-D-galacto-non-2-ulopyranosyl)onate]-
hexane 
 
 To a stirring solution of compound 2 (0.11 g, 0.20 mmol) in a mixture of THF and H2O 
(2.0 ml, 1:1), PPh3 (62 mg, 0.24 mmol) was added and the reaction was heated at 40 °C for 12 h. 
The solvent was removed in vacuo and purified by column chromatography using DCM:MeOH 
(10:1). To this compound (0.10 g, 0.16 mmol) in DCM (0.01 L), TEA (0.3 ml, 1.6 mmol) was 
added and the reaction was stirred for 10 min at rt. Then 1,3-bis(tert-butoxy-carbonyl)-2-methyl-
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2-thiopseudourea (55 mg, 0.19 mmol) and HgCl2 (51 mg, 0.19 mmol) were added and the 
reaction was stirred for 12 h. Next, the reaction mixture was washed with H2O (25 ml, 1x) and 
brine (25 ml, 1X). The organic layers were separated, dried over Na2SO4 and concentrated in 
vacuo. Product was purified using column chromatography with hexane:acetone (3:1 ratio) to 
yield a clear oil (0.12 g, 80% yield). 1H NMR (400 MHz, CDCl3) δ 11.30 (s, 1H), 8.35 (d, J = 
8.0 Hz, 1H), 6.05 (d, J = 8.0 Hz, 1H), 5.37-5.29 (m, 2H), 4.36-4.33 (m, 1H), 4.06 (s, 3H), 3.54 (t, 
J = 12, 4.0 Hz, 2H), 2.82-2.74 (m, 2H), 2.56-2.53 (m, 1H), 2.17 (s, 3H), 2.14 (s, 3H), 2.04 (s, 
3H), 1.83 (s, 4H), 1.48 (s, 24H). 13C NMR (100 MHz, CDCl3) δ 170.8, 170.7, 170.2, 170.1, 
168.8, 163.0, 156.8, 152.7, 83.8, 83.3, 79.5, 75.4, 69.0, 67.8, 62.4, 52.9, 50.5, 49.7, 45.0, 38.8, 
32.4, 29.1, 28.7, 28.3, 28.0, 27.9, 26.4, 23.0, 21.2, 21.0, 20.8. HRMS (ESI): Calculated for 
C35H57ClN4O14S: 824.3281; Found: 825.3348 (M+H).  
 To a stirring solution of the chloro compound (47 mg, 0.06 mmol) in DMF (1.0 ml), 
NaN3 (39 mg, 0.60 mmol) was added and stirred at 60 oC. After 12 h, the reaction mixture was 
quenched with H2O and extracted with DCM (25 ml, 3x). The organic layers were collected and 
washed with brine (25 ml, 1x), dried over Na2SO4 and concentrated in vacuo, to yield a clear oil 
(40 mg, 85% yield). 1H NMR (400 MHz, CDCl3) δ 11.31 (s, 1H), 8.40 (d, J = 7.0 Hz, 1H), 6.03 
(d, J = 8.7 Hz, 1H), 5.33 (t, J = 15.6 Hz, 4H), 4.35 (d, J = 12.4 Hz, 2H), 4.14 – 3.94 (m, 4H), 
3.91 – 3.69 (m, 7H), 3.27 (t, J = 6.8 Hz, 4H), 2.99 – 2.47 (m, 9H), 2.17 (s, 5H), 2.15 (s, 5H), 2.05 
(s, 6H), 1.84 (s, 5H), 1.60 (d, J = 6.3 Hz, 6H), 1.49 (s, 22H), 1.39 (s, 10H), 1.26 (s, 8H). 13C 
NMR (100 MHz, CDCl3) δ 170.8, 170.6, 170.2, 170.1, 168.8, 162.9, 156.8, 152.7, 83.8, 83.3, 
79.5, 77.3, 77.0, 76.7, 75.4, 69.0, 67.8, 62.4, 52.9, 51.3, 50.4, 49.7, 38.8, 29.7, 29.1, 28.7, 28.7, 
28.3, 28.0, 26.2, 23.0, 21.2, 21.0, 20.8. HRMS (ESI): Calculated for C35H57N7O14S: 831.3684; 
Found: 832.3695 (M+H). 
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Compound 4: tert-Butyl(7-((3,5-bis(prop-2-yn-1-ylcarbamoyl)phenyl)amino)-7-oxoheptyl) 
carbamate.  
 
 To a stirring solution of the known spacer (64 mg, 0.26 mmol) in THF (5.0 ml), CDMT 
(91 mg, 0.52 mmol) and NMM (52 mg, 0.52 mmol) was added at 0 oC. In a separate flask, the 
known dimeric scaffold 2 was dissolved in THF (5 ml) with NMM (52 mg, 0.52 mmol) at 0 oC 
and added to the activated acid and stirred for 12 h.  The reaction mixture was quenched with 
H2O, extracted with EtOAc (10 ml, 3x), dried over Na2SO4 and concentrated in vacuo.  The 
compound was purified using flask chromatography with hexane: acetone (3:1) to yield a white 
solid (96 mg, 80% yield). 1H NMR (400 MHz, CDCl3) δ 9.39 (s, 1H), 8.27 (s, 2H), 8.04 (s, 1H), 
7.75 (s, 2H), 4.80 (s, 1H), 4.17 (s, 4H), 3.00 (d, J = 6.1 Hz, 2H), 2.25 (t, J = 37.5 Hz, 5H), 1.42 (s, 
15H).  13C NMR (100 MHz, CDCl3) δ 173.00, 166.66, 159.37, 139.39, 134.58, 121.77, 79.42, 
77.36, 77.05, 76.73, 71.69, 56.03, 37.05, 31.58, 30.94, 29.79, 28.60, 28.45, 26.29, 25.27, 22.64, 
14.11.  HRMS (ESI) Calculated for C26H34N4O5: 482.2529; Found: 505.2404 (M+Na).   
Compound 5a:  
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 To a stirring solution of 3a (40 mg, 0.06 mmol) in THF/ H2O (1.0 ml, 1:1), 4 (9.6 mg, 
0.02 mmol) was added.  CuSO4 (10 mg, 0.04 mmol) was added along with sodium L-ascorbate 
(7.9 mg, 0.04 mmol) and the reaction was stirred at rt for 12 h. Solvent was removed in vacuo 
and product was purified using flash column chromatography with DCM:MeOH (10:1) to yield 
5a (33 mg, 60% yield).  1H-NMR (400 MHz, CDCl3)  δ  9.21 (s, 1H), 8.35 (s, 3H), 8.07 (s, 3H), 
6.08 (s, 2H), 5.53 (d, J = 8 Hz, 2H), 5.36-5.31 (m, 5H), 4.70 (s, 5H), 4.32-4.29 (m, 6H), 4.07 (dd, 
J = 4, 12 Hz, 2H), 3.99-3.92 (m, 2H), 3.78-3.75 (m, 3H), 3.71 (s, 6H), 3.55 (d, J = 8 Hz, 2H), 
3.10 (d, J = 4 Hz, 2H), 2.72-2.65 (m, 6H), 2.55-2.51 (m, 2H), 2.38 (s, 2H), 2.19 (m, 3H), 2.13 ( s, 
6H), 2.02 (s, 6H), 1.98 (s, 6H), 1.93 (s, 6H), 1.45 (s, 12H), 1.36 (s, 27H), 1.27 (s, 12H).  13C 
NMR (100 MHz, CDCl3)  δ 210.8, 172.3, 171.3, 170.7, 170.1, 170.0, 168.8, 166.6, 156.3, 156.1, 
139.7, 135.0, 134.9, 123.1, 121.5, 121.44, 121.4, 121.3, 83.5, 79.7, 79.13, 79.11, 77.9, 77.6, 77.5, 
77.2, 76.6, 76.5, 74.4, 69.5, 68.4, 68.2, 68.0, 62.4, 53.8, 52.9, 51.0, 50.3, 50.2, 50.15, 50.08, 
50.00, 40.5, 40.4, 38.8, 37.2, 37.1, 35.5, 35.4, 31.9, 31.8, 29.9, 29.8, 29.78, 29.7, 29.6, 29.5, 29.4, 
29.3, 28.8, 28.7, 28.73, 28.69, 28.65, 28.62, 28.5, 28.4, 28.3, 28.2, 28.18, 28.14, 27,3, 27.2, 26.4, 
25.9, 25.6, 25.5, 25.4, 25.3, 25.2, 23.3, 23.2, 22.7, 22.6, 21.1, 21.0, 20.8, 20.7, 14.1.  HRMS (ESI) 
Calculated for C84H128N14O29S2: 1860.8413; Found: 1923.6098 (M+ 3Na). 
Compound 5b: 
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 To a stirring solution of compound 3b (26 mg, 0.04 mmol) in THF: H2O (1.0 ml, 1:1), 4 
(8.6 mg, 0.017 mmol) was added.  CuSO4 (7.5 mg, 0.38 mmol) was added with sodium L-
ascorbate (6.7 mg, 0.28) and the reaction was stirred for 12h at rt. Solvent was removed in vacuo 
and the product was purified using flash column chromatography with DCM:MeOH (10:1) to 
yield compound 5b (84 mg, 65% yield).  1H NMR (400 MHz, CDCl3) δ 11.30 (s, 2H), 8.50 (d, J 
= 27.2 Hz, 3H), 8.38 – 8.19 (m, 2H), 7.86 – 7.59 (m, 6H), 6.25 (s, 2H), 5.33 (m, 5H), 4.72 (m, 
6H), 4.34 (m, 7H), 4.21 – 4.01 (m, 9H), 3.88 – 3.69 (m, 10H), 3.11 (d, J = 6.1 Hz, 1H), 2.87 – 
2.61 (m, 5H), 2.58 – 2.44 (m, 2H), 2.38-1.87 (m, J = 7.3 Hz, 22H),  1.57 – 1.14 (m, 67H), .  13C 
NMR (101 MHz, CDCl3) δ 170.9, 170.7, 170.2, 168.7, 166.3, 162.9, 156.8, 152.5, 144.6, 134.9, 
122.9, 121.3, 114.1, 83.5, 77.3, 77.2, 77.0, 76.7, 75.0, 68.8, 67.8, 62.5, 56.1, 53.8, 52.9, 50.2, 
35.5, 31.9, 29.8, 29.7, 29.4, 29.3, 28.6, 28.4, 28.2, 27.9, 27.5, 25.8, 23.0, 22.7, 21.2, 20.9, 20.8, 
14.1.  HRMS (ESI) Calculated for C96H148N18O33S2: 2144.9898; Found: 2145.9985 (M+H). 
Compound SC1.   
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 To a stirring solution of compound 3a (10 mg, 16 µmol) in MeOH(1.0 ml), NaOMe (5.4 
M, 0.25 ml) was added.  The reaction was stirred for 1 h, neutralized with Dowex H+ resin until 
the pH was 7.  The resin was filtered, solvent was removed in vacuo and the residue was re-
dissolved in DCM: TFA (1.0 ml, 1:1) and stirred for 1 h and solvent removed in vacuo.  The 
residue was dissolved in EtOH with calaytic amount of Pd(OH)2 and stirred for 8 h.  Reaction 
mixture was filtered and solvent removed, re-dissolved in MeOH (1.0 ml), NaOH (10 mM, 1.0 
ml) was added and stirred for 1 h.  Dowex H+ resin was used to neutralize to pH 7 and solvent 
was removed and compounds were purified with Bio-Gel P-2 Gel with DI water as solvent (5.0 
mg, 75% yield).  1H NMR (400 MHz, D2O) δ 3.72 (t, J = 11.4 Hz, 2H), 3.62 – 3.32 (m, 5H), 
3.22 (s, 1H), 2.87 (t, J = 7.6 Hz, 1H), 2.75 – 2.41 (m, 4H), 1.91 (d, J = 13.9 Hz, 3H), 1.52 (m, 
4H), 1.28 (s, 4H).  HRMS (ESI) Calculated for C17H33N3O7S: 423.2039; Found: 422.1962 (M-1, 
negative ion).   
Compound SC2. 
 
 SC2 was synthesized in a manner from 3b (5.0 mg, 16 µmol) similar to that of Sc1 and 
the product was purified using Bio-Gel P-2 Gel with DI water as solvent to give pure SC2 ( 1.9 
mg, 70 %).  1H NMR (400 MHz, D2O) δ 4.25-4.08 (m, 3H), 3.99 (m, 3H), 3.58-3.55 (m , 1H),  
3.36-3.34 (m, 1H),  3.12-3.07 (m, J = 8.2 Hz, 2H),  2.95-2.78 (m, 1H), 2.44-2.35 (m, 3H), 2.15 (s, 
1H), 2.03 (s, 1H), 1.87 (s, 5H), 1.69-1.54 (m, 3H).  HRMS (ESI) Calculated for C18H35N5O7S 
465.2257; Found:  464.1987 (M-1, negative ion). 
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Compound SC3.   
 
 To a stirring solution of compound 5a (4.0 mg, 2.4 µmol) in MeOH (1.0 ml), NaOMe 
(5.4 M, 0.25 ml) was added.  The reaction was stirred for 1 h, neutralized with Dowex H+ resin.  
The resin was filtered, solvent was removed in vacuo and residue was re-dissolved in DCM/TFA 
(1.0 ml, 1:1) and stirred for 1 h.  Solvent was removed in vacuo, re-dissolved in MeOH (1.0 ml) 
and NaOH (10 mM, 1.0 ml) was added and stirred for 1 h. Dowex H+ resin was used to 
neutralized to pH 7 and solvent was removed. The product was purified with Bio-Gel P-2 Gel 
with DI water as solvent (2.2 mg, 80 % yield ). 1H NMR (400 MHz, D2O) δ 7.88 – 7.69 (m, 5H), 
4.21 (q, J = 6.6 Hz, 2H), 4.06 – 3.90 (m, 1H), 3.76 – 3.44 (m, 11H), 3.30 – 3.14 (m, 2H), 2.90 – 
2.83 (m, 2H), 2.80 – 2.70 (m, 2H), 2.62 – 2.47 (m, 3H), 2.45 – 2.33 (m, 2H), 2.32 – 2.21 (m, 2H), 
1.92 (s, 6H), 1.77 (q, J = 12.9 Hz, 2H), 1.72 – 1.61 (m, 4H), 1.57 – 1.45 (m, 4H), 1.43 – 0.91 (m, 
20H). HRMS (ESI) Calculated for C55H88N14O17S2: 1280.5893; Found: 641.3013 (2M+H). 
Compound SC4 
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  SC4 was synthesized in a manner similar to SC3 using 5b (5.1 mg, 2.4 µmol) to yield a 
white solid (2.3 mg, 70% yield).  1H NMR (400 MHz, D2O) δ 7.99 – 7.73 (m, 5H), 4.28 (d, J = 
6.2 Hz, 1H), 4.05 (s, 1H), 3.83 (m, 3H), 3.65 (m, 10H), 3.48 (dd, J = 25.8, 14.8 Hz, 10H), 2.68 – 
2.43 (m, 5H), 2.46 – 2.23 (m, 4H), 1.87 (s, 6H), 1.81 – 1.46 (m, 10H), 1.42 – 0.98 (m, 18H).  
HRMS (ESI) Calculated for C57H92N18O17S2: 1364.6329; Found 1365.6420 (M+H). 
Compound 7: 5-Acetylamino-4- N-tert-butyloxycarbonyl-6- (1,2,3-triacetoxy-propyl) -5,6-
dihydro-4H-pyran-2-carboxylic acid methyl ester. 
 
 To a solution of compound 665b, 65c (1.5 g, 3.3 mmol) in EtOH (25 ml), Lindlar catalyst 
(0.15 g, 0.10 equivalent) was added. H2 gas was bubbled to the solution and the reaction was 
stirred at rt for 12 h. After filtering using celite, the filtrate was collected and solvent removed in 
vacuo to give a white product (1.4 g, quantitative). To this compound (0.53 g, 1.2 mmol) in THF 
(20 ml), Et3N (1.6 ml, 1.5 mmol) was added. The solution was stirred rt for 30 min and Boc2O 
(0.54 g, 2.5 mmol) was added and reaction stirred for 12h at rt. Upon completion, THF was 
removed in vacuo. The residue was washed using HCl (1M, 25 ml) and extracted by DCM (30 
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ml, 3x), the organic phases were combined and dried over Na2SO4. DCM was removed in vacuo 
and the reaction mixture was purified using column chromatography with hexane: acetone (3:1) 
as eluent to give a white product. (0.56 g, 86% yield). 1H NMR (400 MHz, CDCl3) δ 6.46 (d, J = 
9.0 Hz, 1H), 5.94 (s, 1H), 5.43 (s, 1H), 5.27 (s, 1H), 4.63 (d, J = 12.4 Hz, 1H), 4.44 (d, J = 10.0 
Hz, 1H), 4.35 (d, J = 8.9 Hz, 1H), 4.15 (dd, J = 12.3, 7.1 Hz, 1H), 3.95 (d, J = 9.2 Hz, 1H), 3.77 
(s, 3H), 2.14 (s, 9H), 2.10 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 1.95 (s, 3H). 13C NMR (100 MHz, 
CDCl3) δ 170.9, 170.6, 170.3, 170.0, 161.8, 156.2, 144.6, 111.0, 80.2, 71.4, 67.8, 62.2, 60.4, 52.4, 
50.1, 47.3, 28.2, 23.1, 21.0, 20.9, 20.8, 20.7, 14.2. HRMS. Calculated for C23H34N2O12: 530.2112; 
Found: 531.2181 (M+H) 
Compound 8: 5-Acetylamino-4- N-tert-butyloxycarbonyl-6-[(2,2-dimethyl-[1,3]dioxolan-4-
yl] 5,6-dihydro-4H-pyran-2-carboxylic acid methyl ester.  
 
 To a solution of compound 7 (0.56 g, 1.1 mmol) in MeOH (0.010 L), NaOMe (0.05 eq) 
was added. The solution was stirred at rt for 5 h. The progress of the reaction was monitored by 
TLC. Upon completion, the reaction mixture was neutralized by H+ resin, the suspension was 
filtered. The liquid phase was collected and dried in vacuo to give a colorless compound. To a 
solution of this compound (0.42 g, 1.1 mmol) in dry acetone (0.010 L), H+ resin was added to 
adjust the pH to 4. The solution was stirred at rt for 12 h. The suspension was filtered, acetone 
was removed in vacuo, the residue was washed by saturated NaHCO3, extracted by DCM (3x 
0.020 mL), the organic phases were combined and dried over Na2SO4, DCM was removed in 
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vacuo and the reaction mixture was purified by flash column chromatography using hexane: 
acetone (4:1) to give the 3. (0.41 mg, 88%). 1H NMR (400 MHz, CDCl3) δ 6.65 (d, J = 6.4 Hz, 
1H), 5.79 (s, 1H), 5.08 (d, J = 4.2 Hz, 1H), 4.82 (d, J = 9.0 Hz, 1H), 4.59 (t, J = 9.4 Hz, 1H), 
4.38 (dd, J = 13.5, 5.3 Hz, 1H), 4.26 – 4.06 (m, 2H), 4.01 (d, J = 10.6 Hz, 1H), 3.91 (td, J = 10.1, 
6.7 Hz, 1H), 3.76 (s, 3H), 3.50 (dd, J = 8.3, 4.3 Hz, 1H), 2.03 (s, 3H), 1.44 (s, 9H), 1.40 (s, 3H), 
1.36 (s, 3H). 13C NMR (400 MHz, CDCl3) δ 173.9, 162.0, 157.2, 146.3, 109.2, 107.8, 81.0, 78.3, 
77.3, 77.0, 76.7, 74.0, 69.7, 67.3, 52.4, 52.1, 48.7, 28.2, 27.1, 25.3, 23.0. HRMS (ESI) 
Calculated for C20H32N2O9: 444.2108; Found: 445.2180 (M+H). 
Compound 9: 5-Acetylamino-4-N-tert-butyloxycarbonyl-6- [(2,2-dimethyl-[1,3]dioxolan-4-
yl)- (4-nitro-phenoxycarbonyloxy)-methyl]-5,6-dihydro-4H-pyran-2-carboxylic acid methyl 
ester. 
 
 To a solution of compound 3 (35 mg, 0.079 mmol) in pyridine (0.010 L), DMAP (19 mg, 
0.16 mmol) was added. The solution was stirred at rt for 30 min and 4-nitrophenylchloroformate 
(32 mg, 0.16 mmol) was added. The reaction was stirred at rt for 16 h. The reaction mixture was 
washed by HCl (1 M, 0.025 L) and extracted with DCM (3 x 0.020 L), the organic phases were 
combined and dried over Na2SO4. DCM was removed in vacuo and the product was purified by 
column chromatography using hexane: acetone (3:1) to give 4. (39 mg, 80% yield).  1H NMR 
(400 MHz, CDCl3) δ 8.27 (d, J = 8.9 Hz, 2H), 7.50 (d, J = 8.9 Hz, 2H), 5.97 (d, J = 9.6 Hz, 1H), 
5.90 (s, 1H), 5.31 (t, J = 5.7 Hz, 1H), 4.81 (d, J = 9.6 Hz, 1H), 4.54 (t, J = 9.7 Hz, 1H), 4.47 – 
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4.29 (m, 2H), 4.24 (dd, J = 8.9, 5.7 Hz, 2H), 4.17 – 4.05 (m, 1H), 3.79 (s, 3H), 1.95 (s, 3H), 1.42 
(s, 9H), 1.41 (s, 3H), 1.38 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 171.3, 161.6, 156.4, 155.7, 
152.5, 145.6, 144.8, 125.2, 122.3, 110.5, 108.9, 80.6, 77.3, 77.0, 76.7, 75.1, 74.2, 65.5, 52.5, 49.5, 
48.1, 28.2, 26.4, 25.5, 23.2. HRMS (ESI) Calculated for C27H35N3O13: 609.2170; Found: 
632.2057 (M+Na). 
Compound 10a: 5-Acetylamino-4-N-tert-butyloxycarbonyl-6-[(6-azido-hexylcarbamoyloxy) 
-(2,2-dimethyl-[1,3]dioxolan-4-yl)-methyl]-5,6-dihydro-4H-pyran-2-carboxylic acid methyl 
ester. 
O
N
H
N3
O
NHBoc
COOMe
AcHN
O
O O
 
 To a solution of 6-azidohex-1-amine (19 mg, 0.13 mmol) in CH3CN (8.0 ml), Et3N (20 
mg, 0.19 mmol) was added. The solution was stirred at rt for 30 min. 9 (39 mg, 0.064 mmol) in 
CH3CN (2.0 ml) was added. The reaction was stirred at rt for 3 h. The progress of the reaction 
was monitored by TLC. Upon completion, CH3CN was removed in vacuo and the reaction 
mixture was washed by HCl (1 M, 0.025 L), extracted by DCM (3 x 0.020 L), the organic phases 
were combined and dried over Na2SO4. DCM was removed in vacuo and the product was 
purified by column chromatography using hexane: EtOAc (1:1) to give 5. (35 mg, 89%). 1H 
NMR (400 MHz, CDCl3) δ 6.15 (d, J = 9.4 Hz, 1H), 5.90 (s, 1H), 5.24 (d, J = 3.7 Hz, 1H), 5.01 
– 4.83 (m, 2H), 4.51 (t, J = 8.9 Hz, 1H), 4.33 (dd, J = 13.6, 7.8 Hz, 2H), 4.19 – 4.04 (m, 2H), 
4.04 – 3.92 (m, 2H), 3.76 (s, 3H), 3.73(s, 1H) 3.24 (t, J = 6.9 Hz, 2H), 3.11 (dt, J = 20.7, 6.6 Hz, 
2H), 1.93 (s, 3H),  1.66 – 1.53 (m, 2H), 1.48 (m, 2H), 1.41 (m, 2H), 1.39 (s, 9H), 1.34(s, 3H), 
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1.23(s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.8, 162.1, 156.2, 155.5, 144.4, 111.4, 108.9, 80.1, 
74.9, 69.7, 65.9, 52.4, 51.3, 50.0, 47.6, 41.1, 29.6, 28.7, 28.3, 26.4, 26.3, 26.3, 25.4, 23.2. HRMS 
(ESI) Calculated for C27H44N6O10: 612.3119; Found: 635.3006 (M+Na). 
Compound 10b: 5-Acetylamino-4-[2,3-bis(tert-butoxycarbonyl)guanidine]-6-[(6-azido-
hexyl carbamoyloxy)-2,3 dihydroxy propyl]-5,6-dihydro-4H-pyran-2-carboxylic acid 
methyl ester. 
O
N
H
N3
O
NH
COOMe
AcHN
HO
HO O
NHBoc
BocN
 
 To a solution of compound 10a (40 mg, 0.084 mmol) in THF (3.0 ml), TFA (3.0 ml) was 
added, the reaction was stirred at rt for 1 h. THF was removed in vacuo, Et3N (26 µl, 0.25 mmol) 
was added. The solution was stirred at rt for 30 min. HgCl2 (27 mg, 0.10 mmol) and 1,3-Bis(tert-
butoxycarbonyl)-2-methyl-2-thiopseudourea (29 mg, 1.2 mmol) was added. The reaction was 
stirred at rt for 12 h. The reaction mixture was washed with HCl (1M, 0.025 L), extracted with 
DCM (3 x 0.010 L), DCM was removed in vacuo and the product was purified by column 
chromatography using DCM: MeOH (25:1) to give the product 10b. (50 mg, 84%). 1H NMR 
(400 MHz, CDCl3) δ 11.40 (s, 1H), 8.54 (d, J = 8.7 Hz, 1H), 7.39 (s, 1H), 7.28 (s, 1H), 6.85 (s, 
1H), 5.89 (s, 1H), 5.32 (s, 1H), 5.20 (t, J = 9.5 Hz, 1H), 5.03 (t, J = 5.7 Hz, 1H), 4.82 (d, J = 9.4 
Hz, 1H), 4.49 (d, J = 10.5 Hz, 1H), 4.37 (dd, J = 19.7, 10.0 Hz, 1H), 4.14 (dd, J = 14.2, 7.1 Hz, 
1H), 4.05 (d, J = 9.2 Hz, 1H), 3.80 (s, 3H), 3.68 (dd, J = 24.9, 12.7 Hz, 1H), 3.27 (t, J = 6.8 Hz, 
2H), 3.17 (ddd, J = 19.4, 13.4, 6.8 Hz, 2H), 1.95 (d, J = 10.0 Hz, 3H), 1.60 (dd, J = 13.8, 6.8 Hz, 
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2H), 1.50 (s, 18H), 1.38 (s, 4H), 1.27 (dd, J = 7.7, 6.5 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 
171.0, 162.8, 162.4, 162.2, 162.1, 157.1, 157.1, 152.5, 144.9, 118.2, 115.3, 110.5, 83.7, 79.7, 
69.4, 68.7, 62.4, 53.5, 52.31, 51.26, 49.4, 47.1, 45.7, 41.2, 29.4, 28.7, 28.3, 28.2, 28.1, 27.9, 27.9, 
26.3, 26.2, 22.7, 8.4. HRMS (ESI) Calculated for C30H50N8O12: 714.3548; Found: 715.3627 
(M+H). 
Compound 11a:  
 
 To a solution of 10a (54 mg, 0.088 mmol) in THF/H2O (1.0 ml, 1:1), 4 (18 mg, 0.036 
mmol) was added. CuSO4 (15 mg, 0.10 mmol) was added along with sodium L-ascorbate (0.020 
g, 0.10 mmol ). The reaction was stirred at rt for 12 h. Upon completion by TLC, solvent was 
removed in vacuo and the product was purified by column chromatography using EtOAc: MeOH 
(30:1) to give 11a. (48 mg, 78%). 1H NMR (400 MHz, CDCl3) δ 8.23(s, 3H), 7.83 (s, 2H), 6.67 
(s, 2H), 5.95 (s, 2H), 5.64 (s, 1H), 5.24(s,3H), 4.60(m, 6H), 4.33(s, 8H), 4.12 (s, 8H), 3.98 (s, 
2H), 3.71 (s, 6H), 3.04 (d, J =33.2Hz, 4H)2.40 (s, 1H), 2.19 (s, 2H), 2.09 (s, 2H), 2.06 (s, 2H), 
1.90 (s, 10H), 1.68 (s, 2H), 1.44 (s, 14H), 1.26– 1.36 (m, 42H). HRMS (ESI) Calculated for 
C80H122N16O25: 1706.8767; Found: 1707.8838(M+H). 
Compound 11b:  
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 To a solution of 10b (40 mg, 0.056 mmol) in THF/H2O (1.0 ml, 1:1), 4 (13 mg, 0.025 
mmol) was added. CuSO4 (14 mg, 0.088 mmol) was added with sodium L-ascorbate (17 mg, 
0.088 mmol). The reaction was stirred at rt for 12 h. Upon completion, solvent was removed in 
vacuo and the product was purified by column chromatography using EtOAc : MeOH (20:1) to 
give 9. (38 mg, 80%). 1H NMR (400 MHz, CDCl3) δ 11.38 (s, 1H), 9.74 (s, 1H), 8.19 (m, 5H), 
7.28 (s, 2H), 5.89 (s, 2H), 5.31 (s, 6H), 5.21 – 5.05 (m, 2H), 4.78 (s, 2H), 4.52 (s, 5H), 4.17 – 
3.90 (m, 4H),4.09-3.85 (m, 4H), 3.80-3.74 (m, 8H), 3.54 (s, 2H), 3.36 (s, 1H), 3.30 – 2.72 (m, 
6H), 2.35 (d, J = 13.9 Hz, 2H), 2.05 (s, 2H), 1.81 (s, 7H), 1.54 (m, 22H), 1.45 – 1.33 (m, 12H), 
1.33 – 0.99 (m, 28H), 0.90-0.84 (m, 10H). HRMS(ESI) Calculated for C86H134N20O29: 1910.9626; 
Found: 1912.0572(M+H) 
Compound SC5: 
 
 To a solution of compound 10a (1.8 mg, 0.29 µmol) in MeOH (5.0 ml), NaOH (0.50 M, 
1.0 ml) was added. The solution was stirred at rt for 2 h. The progress of the reaction was 
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monitored by TLC. Upon completion, the reaction mixture was neutralized by H+ resin, the 
suspension was filtered. The filtrate was collected and dried in vacuo. The residue was added to 
DCM/TFA (5.0 ml, 1:1), the mixture was stirred at rt for 1 h. DCM was removed in vacuo, the 
product was dissolved in EtOH (5.0 ml), Lindlar catalyst (10%) was added. H2 gas was bubbled 
to the solution and stirred at rt for 12 h. The suspension was filtered and the filtrate, which 
contained product SC5, was collected and crude product was purified by Biogel P2 column to 
give pure SC5 (1.0 mg, 76%).  1H NMR (400 MHz, D2O) δ 5.73 (s, 1H), 4.34 – 4.23 (m, 2H), 
4.16 – 4.04 (m, 2H), 3.71 – 3.57 (m, 1H), 3.39 (dt, J = 13.3, 6.8 Hz, 2H), 3.02 (s, 4H), 1.98 (s, 
3H), 1.55 – 1.30 (m, 4H), 1.23-1.18 (m, 4H). HRMS (ESI) Calculated for C18H32N4O8, 432.2220. 
Found: 433.2292 (M+H). 
Compound SC6: 
 
 SC6 was synthesized in a manner similar to that of SC5 using 10b (1.6 mg, 0.22 µmol) 
and the crude product was purified by P2 column to give the SC6 (0.75 mg, 72%).  1H NMR 
(400 MHz, D2O) δ 5.63 (s, 1H), 4.38 – 4.18 (m, 2H), 4.10-3.87 (m, 2H), 3.74-3.61(m, 2H), 3.38 
(t, J = 7.2 Hz, 1H), 3.02 (s, 4H), 1.93 (s, 3H), 1.52 – 0.99 (m, 8H). HRMS (ESI) Calculated for 
C19H34N6O8: 474.2438; Found: 475.2516 (M+H). 
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Compound SC7: 
 
  To a solution of compound 11a (4.5 mg, 0.26 µmol) in MeOH (5.0 ml), NaOH (0.50 M, 
1.0 ml) was added. The solution was stirred at rt for 2 h. The progress of the reaction was 
monitored by TLC. Upon completion, the reaction mixture was neutralized by H+ resin and the 
suspension was filtered. The filtrate was dried in vacuo and DCM/TFA (1:1, 5.0 ml) was added 
to the residue and was stirred at rt for 1 h. After removal of solvent, the crude product was 
purified by P2 column to give SC7. (2.4 mg, 70%). 1H NMR (400 MHz, D2O) δ 7.89 (s, 2H), 
7.80 (s, 3H), 5.91 (s, 2H), 4.84 (d, J = 9.4 Hz, 2H), 4.54 (s, 2H), 4.47 (d, J = 10.5 Hz, 2H), 4.29 
(s, 3H), 4.25 – 4.08 (m, 3H), 3.96 (s, 4H), 3.53 (d, J = 9.8 Hz, 2H), 3.37 (dd, J = 11.9, 6.4 Hz, 
2H), 2.88 (d, J = 7.4 Hz, 4H), 1.90 (s, 6H), 1.76 (s, 2H), 1.57 (s, 2H), 1.30 (s, 6H), 1.13-1.05 (m, 
14H), 0.70-0.63 (m, 6H). HRMS (ESI) Calculated for C57H86N16O19: 1298.6255; Found: 
1299.6329(M+H). 
Compound SC8:  
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 SC8 was synthesized in a manner similar to SC7 using 11b (3.5 mg, 0.18 µmol) and the 
crude product was purified by P2 column to give SC8. (2.0 mg, 79%). 1H NMR (400 MHz, D2O) 
δ 7.89 (s, 5H), 5.80 (d, J = 17.5 Hz, 2H), 4.44 (d, J = 10.1 Hz, 2H), 4.38 (d, J = 8.5 Hz, 2H), 4.34 
– 4.20 (m, 4H), 4.16 (dd, J = 26.4, 10.1 Hz, 2H), 4.01 (dt, J = 13.9, 6.9 Hz, 4H), 3.62 (d, J = 8.8 
Hz, 2H), 3.51 (d, J = 11.6 Hz, 1H), 2.99 – 2.79 (m, 5H), 2.29 (d, J = 7.5 Hz, 2H), 1.96 (s, 2H), 
1.95 – 1.85 (m, 5H), 1.82 (d, J = 14.9 Hz, 2H), 1.71 (s, 3H), 1.54 (s, 4H), 1.27 (s, 8H), 1.20 – 
1.11 (m, 6H), 1.06 (s, 6H). HRMS (ESI) Calculated for C57H86N16O19:1382.6691; Found: 
1383.6761(M+H). 
1.2.6.4 Immobilization of Glycans 
 Synthetic glycans were covalently immobilized onto Nexterion® NHS slides using 
DIGILAB Omnigrid Micro printer in 300 mM phosphate buffer with 0.005% Tween-20 at pH 
8.5. Each glycan was printed twenty times in quintuplicate at 200 µM concentration.  Following 
printing, the glycans were allowed to react for 30 min at 60% humidity. After overnight 
desiccation, the slides were blocked for 60 min with 50 mM ethanolamine in 50 mM boric acid 
buffer (pH 9.5), washed 3 times with deionized (DI) water, dried and stored at -20°C. 
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1.2.6.5 Limit of Detection Assay 
 To determine limit of detection, a serial 10 fold dilution was performed for 
A/Brisbane/59/2007, A/Solomon Islands/2006 and A/Aichi/2/1968 strains. The concentration of 
A/Brisbane/59/2007 was tested from 2.4 x 106-2.4 x 101 PFU (Plaque Forming Units), 
A/Solomon Islands/3/2006 from 9.0 x 106 - 9.0 x 101 PFU and A/Aichi/2/1968 from 1.5 x 106 -
1.5 x 101 PFU. Each concentration of virus was applied to the microarray for 60 min in a buffer 
consisting of PBS, 2% BSA and 0.05% Tween-20. Post-virus incubation and wash (three times 
with PBS and 0.05% Tween-20 and two times with PBS), antibodies specific to each virus were 
diluted and added to the microarray for 60 min. For A/Brisbane/59/2007, ferret hyperimmune 
sera to influenza A/Brisbane/59/2007 (H1N1), NR-19260 was diluted 5000 fold, for A/Solomon 
Islands/3/2006 ferret hyperimmune sera to influenza A/Solomon Islands/3/2006 (H1N1), NR-
19262 was diluted 1000 fold and for A/Aichi/2/1968 polyclonal anti-influenza virus 
A/Aichi/2/1968 (H3N2) antiserum chicken, NR-3125 was diluted  5000 fold. Slides were washed 
as previously described above and incubated for 60 min with the appropriate fluorescently 
tagged secondary antibodies. For A/Brisbane/59/2007, anti-ferret IgG, IgA, IgM (H+L) 
rhodamine antibody was diluted  10,000 fold, for A/Solomon Islands/3/2006 anti-ferret IgG, IgA, 
IgM (H+L) rhodamine antibody was diluted 5000 fold and for A/Aichi/2/1968 Alexa Fluor® 633 
goat anti-chicken IgG (H+L) was diluted 20,000 fold. The slides were washed as described 
above, followed by a DI water rinse. The slides were dried and scanned using the 
GenePix®4000B scanner. A/Brisbane/59/2007 and A/Solomon Islands/3/2006 were scanned at 
532nm and A/Aichi/2/1968 at 635nm.  All experiments were performed in triplicate. 
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1.2.6.6 Drug Susceptibility Assay 
 To determine drug susceptibility for A/Brisbane/59/2007, A/Solomon Islands/3/2006 and 
A/Aichi/2/1968, each virus strain, 105 PFU, was premixed with 10 ng of antiviral Zanamivir® or 
Oseltamivir®, for 30 min at rt. The premixed sample was subsequently added to the microarray 
and allowed incubate for 60 min. Fluorescence intensity was measured as previously described in 
the limit of detection methods. All experiments were performed in triplicate. 
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1.3 Electrochemical Assay to Detect Influenza Virus and Measure Drug Susceptibility 
 
 
 
 
 
 
 
 
 
 
 
 
 
 This part of the thesis has been published. (Zhang, Xiaohu, et al. "Electrochemical Assay 
to Detect Influenza Viruses and Measure Drug Susceptibility." Angewandte Chemie 127. 20. 
2015. 6027-6030).  
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1.3.1 Abstract 
  We report a novel electrochemical assay that targets the Neuraminidase (NA) enzyme of 
the virus. Exposure of a glucose bearing electrochemically inactive substrate specific for NA 
releases glucose. Glucose was detected using an electrochemical cell. Using this approach, we 
successfully detected a library of nineteen unique H1N1 and H3N2 influenza strains using 
disposable screen printed electrode strips and an electrochemical cell in less than 1 hour. We also 
demonstrated drug susceptibility of two major antivirals, Zanamivir, and Oseltamivir using the 
assay. The limit and range of detection of this first generation assay is 102 and 102-108 plaque 
forming units (PFU), respectively. While we have focused on influenza in this report, other 
enzymes, e.g. beta-lactamase, hydrolases, sulfatases, present in hard to detect pathogens can be 
identified and drug susceptibility measured rapidly using appropriately designed glucose 
releasing substrates. Existing, ubiquitous, user friendly glucose meters, used by millions 
worldwide to determine glucose concentration in the blood, can now be recalibrated to detect 
enzymes present in pathogens or in the host. 
1.3.2  Introduction  
 As mentioned in Chapter 1, rapid and accurate determination of influenza viruses is 
important to reduce disease burden.69 Several tests are available, but none of them can meet the 
seven different ASSURED criteria. We envisioned a rapid diagnostic test that would be 
selective, sensitive, user friendly, inexpensive, and can be used in different settings. The blood 
glucose monitoring test used by millions worldwide satisfies all these needs and can measure 
glucose within minutes using a battery operated device and disposable strips multiple times in a 
day.70 Our innovation is to develop assays that can use existing, widely adopted, off the shelf 
sensors like the glucose meters to detect influenza viruses. The strategy was to develop and 
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expose substrates containing glucose to enzymes integral to the lifecycle of influenza virus. 
(Figure 1.25) Presence of glucose would indicate presence of the enzyme, and by inference, the 
virus. The virus can be quantified because the amount of glucose released is directly proportional 
to the enzyme activity. Drug susceptibility can be measured as the two major antivirals, 
Zanamivir and Oseltamivir, are enzyme inhibitors. We choose to measure glucose concentration 
after 1 hour of incubation with the virus using disposable test strips, however, a continuous 
measurement system can also be designed.   
1.3.3 Design and Synthesis 
Figure 1.25 Electrochemical assay detect influenza virus 
Sialic acid derivative SG1 can be cleaved by influenza virus to release glucose, which can be detected by 
a glucose meter set up. This process will represent the presence of influenza virus. 
 
 As mentioned in Chapter 1, Hemagluttinin (HA) and Neuraminidase (NA) are two 
important surface proteins on the surface of the virus. HA is implicated in viral entry and NA is 
the enzyme that cleaves N-acetylneuraminic acid (sialic acid) from the surface of host cells to 
facilitate release of viral progeny.5 There are approximately 50-100 copies of NA on the viral 
surface as determined by immunogold labeling and cryo-electron tomography.71 Since NA is 
present as a tetramer with four active sites, there are approximately 200-400 individual units 
capable of cleaving sialic acids, which makes it a suitable target for biosensing applications. We 
synthesized a sialic acid derivative, (SG1) where sialic acid is attached to the 6 position of D-
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NA or virus added).  Membrane free influenza viral NA from two different strains (N1 from 
strain H5N1 A/Anhui/1/2005 and N2 from strain A/Babol/36/2005) was incubated for 2 hours at 
rt in PBS buffer with SG1.  The sample was analyzed for the presence of glucose directly 
without further sample preparation. We determined that glucose was released as determined by 
the current measured amperometrically, which indicated that complete cleavage of SG1 had 
occurred. (Figure 1.29, samples A, B).  The positive control (Figure 1.29, sample P) was a 
solution with glucose as the only analyte in PBS buffer. These studies proved that viral NA 
cleaves SG1 to release glucose, which can be measured using a standard electrochemical setup.  
 Next, we tested three influenza strains, H1N1 A/Brisbane/59/2007, H3N2 
A/Aichi/2/1968, and H3N2 A/HongKong/8/68, which were quantified by plaque assays and rRT-
PCR. (Figure 1.35). Introduction of 100 µL of UV inactivated virus to SG1 and incubation for 2 
hours, releases glucose. (Figure 1.29, Samples C, D, E). The cleavage was confirmed by mass 
spectral analysis. The mass spectra of the control where there is no virus or NA revealed a peak 
at m/z 494.1497 (M+Na, positive ion) corresponding to uncleaved SG1. A new peak emerges at 
m/z, 181.0711 (M+1, positive ion) corresponding to glucose when virus or NA is added. 
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NA. (Figure 1.31, sample B NA + Z). Therefore, we can distinguish between BNA and viral NA 
using the antivirals. 
 We obtained nasal and throat swabs from healthy volunteers and tested for the presence 
of glucose. There was no glucose present in any of the samples. Next, we spiked 105 PFU of 
H1N1 A/Brisbane/59/2007 strains and tested the sample for glucose. We found that the matrix 
does not affect the cleavage of the lead compound SG1 (Figure 1.32), indicating that this assay 
can be used in a point of care setting. 
 Since commercial glucose meters use disposable screen-printed enzyme electrodes for 
blood glucose measurements, we used disposable printed electrodes (CH instruments, Austin, 
Texas) for the next set of experiments. (Figure 1.26)  We introduced glucose oxidase to the strips 
after activation and tested a library of twenty H1N1 and H3N2 influenza strains that were 
quantified using plaque assays and rRT-PCR. Strains were incubated with SG1 (1 mM) using a 
specific set of buffers and reagents to release the viral NA from the membranes as described in 
the supplementary materials for 1 hour before introduction of 20 µL of the solution to the 
disposable strips. We found that all strains release glucose, most strains release SG1 with high 
efficiency in one hour. However, some strains require longer time to completely cleave SG1. 
(Figure 1.34, Table 1.2) We note that, despite variations in printed electrodes from different 
manufacturer or different batches from the same manufacturer which affects the performance, 
the assay detects all strains. The advantages of printed electrodes compared to our previous setup 
is the limited volume of solution needed (20 µL) and the user friendliness of the system. We also 
determined the analytical sensitivity using one of the strains using this rudimentary setup. 
(Figure 1.33) This limit of detection and range is 102 and 102-108 PFU, respectively. 
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Figure 1.34 Fluorescence experiments to demonstrate relative NA activity of four different 
strains. 
MUNANA (10 μL, 1mM) was added to 100 μL of virus strains. Fluorescent intensity was monitored 
using a microplate reader (Synergy 2, Biotek, Inc. Winooski, VT) at 2 min intervals for 1 hour at 37 oC 
after the addition of the substrate. Fluorescent intensity was read at 460 nm with an excitation at 360 nm. 
 
 
Figure 1.35 Images of plaque assay for one strain. 
 92 
 
Confluent MDCK cells were infected with approximately 60, 6 and 0 viral particles (A/Brisbane/59/2007) 
and incubated for 5 days with a semi-solid media overlay. Plaque forming units (PFU) were counted after 
fixing and staining the cells. 
  
   
Influenza strains Plaque Assaya
rRT-PCR 
(CT)b 
Electrochemical 
assay. (x 10-8 A)c 
No virus + SG1 N/A N/A 3.6 ± 2.2 
No glucose N/A N/A 3.4 ± 1.4 
β-Galactosidase  N/A  N/A 4.2±1.9 
α-Mannosidase  N/A  N/A 4.7±1.6 
Glucose (1mM)    N/A  N/A 124.9 ± 2.3 
A/Wilson-Smith/1933 (H1N1) 4.2 X106 18 99.5 ± 4.4 
A/PuertoRico/8/1934 (H1N1) 1.4 X104 15 13.4 ± 2.0 
A/HongKong/8/1968  (H3N2) 1.5 X 105 22 64.4  ±  5.2 
A/Aichi/2/1968 (H3N2) 1.0 X 105 15 31.3  ± 5.3 
A/Beijing/262/1995 (H1N1) 3.5 X 105 21 118.1  ±  11.6 
A/Nanchang/933/1995 (H3N2) 0.7 X 106 18 15.1 ± 2.8 
A/Sydney/5/1997 (H3N2) 0.8 X 104 29 115.7 ± 4.3 
A/NewCaledonia/20/1999 (H1N1) 4.4 X 107 12 17.7 ± 2.6 
A/SolomonIslands/3/2006 (H1N1) 1.1 X 109 11 79.7 ± 5.0 
A/Uruguay/716/2007 (H3N2) 1.2 X107 20 132.4 ± 6.3 
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A/Brisbane/59/2007 (H1N1) 2.5 X 107 12 106.2 ± 5.1 
A/Brisbane/10/2007 (H3N2) 2.2 X 106 21 78.6 ± 4.9 
A/California/07/2009 (H1N1) 3.6 X 106 13 13.4 ± 1.5 
A/New York/18/2009 (H1N1) 3.5 X 105 17 74.4 +5.6 
A/San Diego/1/2009 (H1N1) 1.2 X 105 19 108.5 ± 12.0 
A/Wisconsin/629-D02452/2009 (H1N1) 0.6 X 105 13 98.9 ± 5.7 
A/Wisconsin/15/2009 (H3N2) 0.5 X 104 26 107.8 ± 5.9 
A/Brownsville/31H/2009 (H1N1) 0.4 X 104 22 91.7 ± 9.7 
A/Victoria/361/2011 (H3N2) 7.0 X 106 26 94.5  ±  2.3 
 
 
Table 1.2  Electrochemical detection of 19 influenza strains and validation with rRT-PCR and 
cell-culture plaque assays. 
1.3.5 Conclusion 
 To summarize, we have developed an electrochemical assay that releases glucose upon 
introduction of influenza viruses. We have successfully detected a library of nineteen influenza 
strains. The assay can be used to measure drug susceptibility, which is a significant advantage 
over current genotypic and phenotypic methods that take time, resources, and a laboratory 
environment with specialized equipment and trained personnel. The assay can be integrated into 
current glucose meters by calibrating the instruments to test nasal or throat swabs for influenza. 
Since glucose meters with disposable test strips are user friendly, ubiquitous, and inexpensive, 
this method has great potential to improve clinical decisions and minimize disease burden due to 
influenza. Finally, this concept is unique because any enzyme, e.g. beta lactamase75 or sulfatases 
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76 present in drug resistant bacterial strains can be detected by blood glucose meters provided 
there are sufficient copies of the enzyme and the drugs being tested are enzyme inhibitors.   
1.3.6 Experiment Section 
1.3.6.1 General Information 
 Glycosylation reactions were performed under argon with solvents dried using a solvent 
purification system (Innovative Technology Inc., Amesbury, MA, USA). Other chemical 
reagents were of analytical grade, used as supplied, without further purification unless indicated. 
The acidic ion exchange resin used was Amberlite® IR-120 (H+) resin. Analytical thin layer 
chromatography (TLC) was performed on silica gel 230-400 mesh (Silicycle, Quebec City, 
Canada). Plates were visualized under UV light, and/or by staining with acidic CeH8Mo3N2O12, 
followed by heating. 1H and 13C NMR spectra were recorded on Bruker 400 MHz spectrometer. 
Chemical shifts are reported in δ (ppm) units using 13C and residual 1H signals from deuterated 
solvents as references. Spectra were analyzed with MNova® (Mestrelab Research, Escondido, 
CA, USA). Electrospray ionization mass spectra were recorded on a Micromass QT 2 (Waters) 
and data were analyzed with MassLynx® 4.0 (Waters, Milford, MA, USA) software. Reported 
yields refer to spectroscopically and chromatographically pure compounds that were dried under 
high vacuum (10–2 mbar) before analytical characterization, unless otherwise specified. 
1.3.6.2 Abbreviations 
 N, N-Dimethyl formamide, DMF; Ethyl acetate, EtOAc; Dichloromethane, DCM; Thin 
layer chromatography, TLC; Methanol, MeOH; Ethanol, EtOH; Sodium hydride, NaH; Benzyl 
bromide, BnBr; Triethylamine, NEt3; tert-Butyldimethylsilyl chloride, TBSCl;  4-
Dimethylaminepyridine, DMAP; Sulphuric acid, H2SO4,; Trifluoromethanesulfonic acid, TfOH; 
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N-Iodosuccinimide, NIS; Sodium methoxide, NaOMe; Palladium hydroxide, Pd(OH)2;  Sodium 
hydroxide, NaOH; Sodium thiosulfate, Na2S2O3; Hydrochloric acid, HCl; Glucose oxidase, GOD. 
1.3.6.3 Synthesis and Characterization 
 
Scheme 1.3 Synthesis route of SG1 
Reagents and Conditions: a) i) Pyridine, TBSCl, DMAP, rt, overnight; ii)  NaH, BnBr, DMF, 0 oC- rt, 3h; 
iii) 1M H2SO4 in MeOH, MeOH, rt, 1h, 27% yield for 2α and 20% yield for 2β over three steps; b) TfOH, 
NIS, DCM, -60 °C, 2h, 75%; c) i) NaOMe, MeOH, rt, 30 min.; ii) Pd(OH)2/C/H2, EtOH, rt, 12h.; iii) 0.05 
M NaOH in H2O, rt, 4h, 93% over three steps. 
Benzyl 2,3,4-tri-O-benzyl-α,β-D-glucopyranoside (2α,β) :  
 
                                                               
 To a solution of compound 1 (1.0 g, 3.7 mmol) in pyridine (0.010 L), TBSCl (0.85 g, 5.5 
mmol) was added, followed by addition of DMAP (0.04 g, 0.37 mmol). The reaction mixture 
was stirred overnight at rt. After completion of reaction as monitored by TLC, the solvent was 
removed using a rotary evaporator and the crude compound was used directly without further 
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purification. To a stirred suspension of NaH (0.89 g, 18 mmol, prewashed with dry hexane to 
remove the oil present in 60% suspension of NaH) in anhydrous DMF (0.010 L), the crude TBS 
compound in DMF (0.010 L) was added at 0 °C. The reaction mixture was stirred under argon 
atmosphere for 30 min. BnBr (2.2 ml, 18 mmol) was added dropwise via syringe and reaction 
mixture was stirred for 3 h. The reaction mixture was quenched with 1M HCl (10 mL), diluted 
with EtOAc (20 mL) and washed with water (2 x 10 mL) and brine (2 x 10 mL). The organic 
layer was dried over Na2SO4 and concentrated under reduced pressure to obtain the tetra benzyl 
protected compound. The crude compound was used directly without further purification. To a 
stirred solution of the crude compound in MeOH (0.020 L), H2SO4 in MeOH (1M, 0.50 mL) was 
added. The reaction mixture was stirred at rt and the reaction progress was monitored by TLC 
using two solvent systems: EtOAc–hexanes (1:9) and EtOAc–hexanes (1:1). After completion of 
reaction as monitored by TLC, the reaction mixture was diluted with EtOAc (20 mL) and washed 
with saturated NaHCO3 (2 x 20 mL) and brine (2 x 20 mL). The organic layer was dried over 
NaSO4, concentrated under reduced pressure and subjected to flash chromatography to give 2 
α(0.55 g, 27% yield over three steps) and 2β (0.40 g, 20% yield over three steps). Spectral data is 
in complete agreement with reported value. 
Methyl 5-acetamido-7,8,9-tri-O-acetyl-5-N,4-O-carbonyl-3,5-dideoxy-D-glycero-α-D-
galacto-non-2-ulopyranosylonate-(2,6)-1,2,3,4-tetra-O-benzyl-α-D-glucopyranoside (4α) : 
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 To the stirred solution of acceptor 2α  (0.20 g, 0.35 mmol) and  donor 374 (0.24 g, 0.38 
mmol) in anhydrous DCM (4.0 ml) under an argon atmosphere at -40 0C, NIS (0.19 g, 0.84 
mmol) was added followed by TfOH (0.52 ml, 0.35 mmol, 10% in anhydrous DCM). The 
reaction mixture was stirred at this temperature for ~2h until complete disappearance of the 
acceptor as determined by TLC. Et3N (0.50 mL) was added to quench the reaction and warmed 
to rt. The reaction mixture was diluted with DCM (20 mL), washed with aqueous solution of 
Na2S2O3 (2 x 10 mL) dried over Na2SO4 and concentrated under reduced pressure. The residue 
was subjected to flash silica gel column chromatography eluting with (hexanes:EtOAc 7:3) to 
afford the 4α (0.27 g, 75 % yield) as a white solid. 1H NMR (400 MHz, CDCl3) : δ 7.45 – 7.26 
(m, 20H), 5.58 (dd, J = 8.9, 1.7 Hz, 1H), 5.45 (ddd, J = 8.5, 6.1, 2.5 Hz, 1H), 4.97 (d, J = 10.8 
Hz, 1H), 4.86 – 4.78 (m, 3H), 4.76 (d, J = 6.1 Hz, 1H), 4.73 – 4.65 (m, 2H), 4.56 (dd, J = 15.0, 
12.2 Hz, 2H), 4.26 (dd, J = 12.4, 2.7 Hz, 1H), 4.20 (dd, J = 10.8, 4.5 Hz, 1H), 4.14 (d, J = 7.2 
Hz, 1H), 4.08 – 3.98 (m, 2H), 3.98 – 3.84 (m, 2H), 3.73 (s, 3H), 3.66 (dd, J = 11.2, 9.4 Hz, 1H), 
3.60 (d, J = 9.4 Hz, 1H), 3.58 – 3.52 (m, 1H), 3.49 (dd, J = 10.6, 2.0 Hz, 1H), 2.94 (dd, J = 12.1, 
3.4 Hz, 1H), 2.49 (s, 3H), 2.15 (s, 3H), 2.12 – 2.06 (m, 1H), 2.04 (s, 3H), 1.81 (s, 3H). 13C NMR 
(100 MHz, CDCl3) : δ 171.8, 170.6, 169.9, 169.9, 168.4, 153.6, 138.8, 138.4, 138.2, 137.1, 
128.4, 128.3, 128.0, 127.9, 127.8, 127.7, 127.5, 99.2, 95.5, 81.9, 79.6, 77.5, 75.7, 75.2, 75.0, 
74.9, 73.0, 71.4, 69.9, 69.0, 68.4, 64.7, 62.8, 59.1, 52.9, 36.6, 24.7, 21.1, 20.7, 20.5. HRMS 
(ESI): Calculated for C53H59NO18Na [M+ Na] 1020.3630; Found 1020.3629. 
Methyl 5-acetamido-7,8,9-tri-O-acetyl-5-N,4-O-carbonyl-3,5-dideoxy-D-glycero-α-D 
galacto-non-2-ulopyranosylonate-(2,6)-1,2,3,4-tetra-O-benzyl-β -D-glucopyranoside (4β): 
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 4β was synthesized in a manner from donor 3 (0.24 g, 0.38 mmol) and 2β (0.20 g, 0.35 
mmol) similar to that of 4β and the product was purified using flash silica gel column 
chromatography eluting with hexanes:Et2OAc (7:3) to afford the compound 4β (0.27 g, 75 % 
yield) as a yellowish solid.1H NMR (400 MHz, CDCl3) : δ 7.46 – 7.24 (m, 20H), 5.65 (d, J = 8.6 
Hz, 1H), 5.52 (dt, J = 8.7, 4.3 Hz, 1H), 4.97 (d, J = 11.5 Hz, 2H), 4.91 (d, J = 10.9 Hz, 1H), 4.82 
(s, 2H), 4.76 (t, J = 11.0 Hz, 2H), 4.68 (dd, J = 10.8, 5.5 Hz, 2H), 4.51 (d, J = 7.9 Hz, 1H), 4.37 
(dd, J = 12.4, 2.8 Hz, 1H), 4.21 (dd, J = 11.2, 4.6 Hz, 1H), 4.11 – 3.95 (m, 2H), 3.76 (s, 3H), 
3.75 – 3.60 (m, 4H), 3.56 – 3.44 (m, 2H), 2.99 (dd, J = 12.3, 3.2 Hz, 1H), 2.51 (s, 3H), 2.16 (s, 
3H), 2.11 (s, 3H), 2.12-2.01 (m, 1H), 1.91 (s, 3H). 13C NMR (100 MHz, CDCl3) : δ 177.5, 171.8, 
170.6, 170.0, 168.3, 153.7, 138.6, 138.4, 138.3, 137.3, 128.4, 128.4, 128.4, 128.3, 128.1, 128.1, 
127.9, 127.9, 127.8, 127.8, 127.7, 127.7, 127.6, 127.6, 102.3, 99.3, 84.5, 82.0, 75.7, 75.20, 75.1, 
74.8, 73.9, 71.5, 71.0, 68.6, 64.6, 62.9, 59.1, 52.9, 36.6, 24.7, 21.2, 20.8, 20.6. HRMS (ESI): 
Calcd for C53H59NO18Na [M+ Na] 1020.3630; Found 1020.3629. 
5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-non-2-ulopyranosylonate-(2,6)-α,β-D-gluco 
pyranoside (SG1) :  
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 4α or 4β (0.060 g, 0.060 mmol) was dissolve in MeOH (0.010 L) and treated with a 30% 
solution of NaOMe (75 µl) in CH3OH and stirred at rt for 1 h. The solution was neutralized with 
Amberlite® IR 120 (H+) resin, filtered and concentrates to dryness. The dried compound was 
treated with Pd(OH)2/C (0.010 g) in absolute EtOH was stirred for 12h at rt under H2 at 1 
atmosphere. After completion of reaction as monitored by TLC, reaction mixture was filtered 
using celite pad, washed with EtOH and combined solvent was concentrate to dryness. The dried 
compound was treated with NaOH (0.05 N, 3.0 mL) and reaction was stirred for 4h. After 
completion of reaction, as monitored by TLC (DCM:MeOH:NH4OH) (8:2:1), reaction was 
neutralized using Amberlite® IR 120 (H+) resin, filter, concentrate and subjected to P-2 gel 
column to furnish SG1. (0.013 g, 93 % yield over three steps) (54:46, ratio determined by 1H 
NMR spectroscopy). 1H NMR (400 MHz, D2O) δ 5.12 (d, J = 3.2 Hz, 1H, H1 α), 4.54 (d, J = 7.8 
Hz,1H, H1 β), 4.07 – 3.86 (m, 2H), 3.86 – 3.69 (m, 7H), 3.68-3.53 (m, 5H), 3.51 – 3.41 (m, 2H), 
3.40 – 3.33 (m, 1H), 3.19-3.14 (m, 1H), 2.63 (dd, J = 12.5, 4.2 Hz, 1H), 1.95 (s, 3H), 1.74-1.68 
(m, 1H) 13C NMR (101 MHz, D2O) δ 177.7, 176.8, 174.7, 95.9, 92.1, 75.6, 74.4, 73.9, 72.3, 72.8, 
71.4, 71.8, 69.5, 69.45, 6.2, 68.2, 67.9, 63.1, 62.9, 62.7, 51.8, 39.7, 22.0. HRMS (ESI): Calcd for 
C17H29NO14Na [M+ Na]+ 494.1486, found 494.1497. 
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1.3.6.4 Cells and Viruses 
 MDCK (Madin-Darby canine kidney) cells were purchased from ATCC® (CCL-34™, 
Manassas, VA) and maintained in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Grand 
Island NY) supplemented with 10% Fetal Bovine Serum (FBS Gibco, Grand Island NY). 
Influenza A virus strains used in this study were obtained from BEI Resources (Manassas, VA). 
1.3.6.5 Nasal and Throat Sample Collection 
 Nasal and throat samples were collected from four healthy volunteers. Dry sterile cotton 
tipped swab was used for each sample collection. Samples were stored in phosphate buffered 
saline (PBS) at 4 °C until subsequent use.   
1.3.6.6 Plaque Assays 
 Virus titers of different influenza strains were determined using standard plaque assays in 
MDCK cells to quantify the amount of virus. MDCK cells were grown to confluency in 6-well 
plates. Once confluent, media was removed from the cells and were washed three times with 
plain DMEM to remove residual FBS. Virus suspension was serially diluted 10-fold and added 
to duplicate wells at 400 µL/ well. Virus was adsorbed for 1 h at 37 °C in a 5.0% CO2 incubator. 
One-hour post-adsorption, virus suspension was removed and Avicel (1.2%, 2.0 mL, FMC 
Biopolymer) supplemented with 2 µg/mL TPCK-trypsin (Sigma-Aldrich, St. Louis, MO) was 
added to each well. Avicel was prepared as described previously.77 Plates were incubated for 5 
days to allow for plaque formation. On day 5, the Avicel overlay was removed carefully from 
each well and the wells were washed two times with 1X PBS followed by methanol (100%) 
fixation. Fixed wells were stained with 0.2% crystal violet and plaques were counted to 
determine virus titers. 
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1.3.6.7 Real-time RT-PCR 
 Viral RNA was extracted according to manufacturer’s instructions using MagMAX viral 
isolation kit (Life Technologies, Grand Island NY). cDNA was synthesized from the viral RNA 
using High Capacity cDNA Reverse Transcription Kit purchased from Applied Biosystems 
(Grand Island, NY). Real time PCR was performed using primers and probe for matrix gene, as 
described previously.78 The oligonucleotide probe sequence is 
5`CTCAGTTATTCTGCTGGTGCACTTGCCA consisting of 5` reporter dye 6-
carboxyfluorescein (FAM) and 3` quencher dye 6-carboxytetramethylrhodamine (TAMRA). The 
forward primer sequence (5` GGACTGCAGCGTAGACGCTT) and two reverse primers 
sequences (5` CATCCTGTTGTATATGAGGCCCAT and 5` 
CATTCTGTTGTATATGAGGCCCAT) were used to facilitate amplification of all the strains. 
PCR mix of 30 µL was prepared using 15 µL TaqMan Universal PCR mix (Applied Biosystems, 
Grand Island NY), 1µM primers, 0.5 µM probe, and 5 µL of cDNA. Real time PCR 
amplification and detection was conducted using Applied Biosystems 7500 Fast Real-Time PCR 
System. 
1.3.6.8 Electrochemical Assay using the 3 electrode system 
 The initial proof of principle studies were performed using three-electrode system.72 
(Figure 1.26) Briefly, a glassy carbon working electrode (GCE, 3.0 mm in diameter), a saturated 
calomel reference electrode, and a platinum counter electrode. Fabrication of the electrode was 
performed by polishing the surface of the glassy carbon electrode on the alumina slurries to form 
a clear mirror followed by washing with distilled water and drying with N2. The electrode was 
coated with coating solution achieved by mixing 1ml of solution A (2 mM Bi (NO3). 5H2O and 
3mM SeO2 in 1:20 diluted nitric acid) and 2 ml of solution B (2mM K3Fe(CN)6, 2mM FeCl3, 
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0.1M KCl and 10mM HCl) followed by cyclic voltammetry scanning from +0.60 V to -0.20 V at 
20 mVs-1 for 30 cycles. After the coating, the electrode was activated by cycling from 0.35 V to -
0.05 V at 50 mVs-1 for 30 times in solution C (0.1M KCl and 10mM HCl). 5 mg of Glucose 
oxidase (GOD) was dissolved in 1 mL of 0.5% chitosan solution (prepared in 2% acetic acid) 
and the resulting GOD (10 µL) solution was dropped on the surface of the electrode to form a 
GOD layer. The GOD layer was air dried to form a firm coated layer on the working electrode. 
To detect the neuraminidase activity of influenza virus, 100-200 µL of virus stock (PFU 
determined by plaque assays) was incubated with SG1 (500 µL, 1x10-3 M) for 1 h. To detect the 
Amperometric response, final solution volume was adjusted to 1 mL. Virus was inactivated 
using UV light or 1% Triton X-100 (Sigma Aldrich, St. Louis MO). The amount of glucose 
released by NA cleavage of SG1 was detected by glassy carbon electrode using electrochemical 
analyzer (CH Instruments Ltd, China) at rt. An amperometric i-t curve at a working potential of 
0.00 V was recorded and the current at 100 seconds (when stable) is reported. Increase in peak 
current correlates with increased glucose concentration, which in turn, reflects the activity of 
influenza virus neuraminidase.  
1.3.6.9 Drug susceptibility studies 
 10 ng of Zanamivir or Oseltamivir carboxylate was premixed with the virus for 30 min. 
Next, the solution was incubated with SG1 for 1 h at rt. and glucose released was measured as 
described in the previous section.  
1.3.6.10 Electrochemical assay using printed electrodes 
 Printed electrodes were purchased from CH instruments, Austin, Texas, USA, coated and 
activated the surface using the solutions as described above. GOD was coated on the surface 
using chitosan as previously described. Next, 100 µL of virus containing solution was mixed 
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with SG1 (100 µL, 2 x10-3 M) for 1 h at 37oC. 20 µL of this solution was dropped onto the 
surface of the test area of printed electrode to test for the presence of glucose as described 
previously. 
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2 Glycan Based Norovirus Detection 
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2.1 Norovirus Introduction 
 Norovirus is a non-enveloped, single-stranded RNA virus. 79 It is a highly contagious 
virus that causes patient stomachs and/or intestines to get inflamed. Typically patients have 
nausea, diarrhea, and vomiting if they get infected by norovirus. It can affect people of all ages, 
especially young children and older adults. In some cases, norovirus infection leads to death, 
although this virus does not have a significant death rate. The virus affects approximately 267 
million people and is responsible for an estimated 2 hundred thousand deaths annually in the 
entire world. 80 There are no vaccines or antivirals available for this disease. 
 Norovirus was previously known as Norwalk virus, which was first identified in 
Norwalk, OH in 1972.81  The Norwalk virus was originally visualized by immune electron 
microscopy as 27nm in size. Cultivating the pathogen in cell culture and in animal model is 
essential to further discover and develop the virology and treatment for norovirus infection, 
however, all attempts have failed thus far. 82. However, recent reports suggest that this virus can 
indeed be grown in culture using B cells, but the results are still under investigation. 74    
 Norovirus belongs to the family Caliciviridae which is a group of small, non-enveloped, 
positive stranded RNA virus. There are five genera in Caliciviridae family including Norovirus, 
Sapovirus, Lagovirus, Nebovirus, and Vesivirus.83 Due to unsuccessful attempts of virus 
cultivation, most of the literature has been focused on the virus protein and nucleic acid 
composition. The human norovirus genome is a linear, positive sense RNA which is 
approximately 7.6kb length.84 The genome is attached to the viral protein genome (VPg) 
covalently. The genome is shown in Figure 2.1. It is comprised of three open reading frames 
including ORF-1, ORF-2, and ORF-3 and encodes eight viral proteins.  
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Figure 2.1 The genome of norovirus. 
Different box represent different domain, which used to translate different proteins. 
Figure is taken from publisher with permission. 80 
 
 Norovirus mutate rapidly and can be descripted as a “shape-shifter”. 80 This description 
was determined by the VP1 amino acid sequence which refers to the virus protein encoding. Six 
genogroups (GI- GVI) and more than 40 genotypes have been identified due to the rapid 
mutation.85 The genetic diversity of the human noroviruses is apparent from the VP1 amino acid 
sequence. For example, the VP1 amino acid sequence of GII.4 strains differs by about 40% from 
the GI.1 norwalk strain and 5%-7% for the GII genotype.86 This variability represents the 
diversity of the norovirus. With the continued evolution, the sequence cutoff of different strains 
is no longer sufficient to classify each other; new approach such as addition of a phylogenetic 
tree would provide more accurate details for the classification of norovirus.87  
2.1.1 Structure of Norovirus 
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Figure 2.2 The x-ray crystallographic structure of the recombinant Norwalk virus capsid and P 
domain. 
a: The T=3 capsid structure of norovirus. 88 b: Representation of the VP1 dimer shows S domain 
(blue), P1 domain (read) and P2 domain (gold). c: The structure of P domain. 
Figure is taken from publisher with permission. 89 
  
 The X-Ray crystallographic structure of the recombinant Norwalk virus capsid was 
shown in Figure 2.2 which clearly represents the structure of the norovirus. 88 The diameter of 
the virus is approximately 390 Å and the capsid exhibits a T=3 icosahedral organization. The 
capsid is formed by 90 dimers of the capsid protein which is composed of two distinct domains 
including the shell (S) domain and protruding (P) domain. The S domain contributed to the 
icosahedral shell formation and the P domain is involved in the dimeric contacts. Because the P 
domain decorates the surface of the virus, it is hypothesized that the P domain would be 
contributed to several biological functions such as causing strain diversity, binding to the host 
cell, and involving in immunogenicity. 
 Figure 2.3 shows the norovirus structure from electron microscope. In this figure, P dimer 
was enlarged from a single virus like particle to represent the HBGA-binding site filling model. 
A tri-saccharide is shown in a stick model binding to the amino acid residues in the P dimer 
binding site.  
  
From left 
binding s
permissio
 
 T
the size f
all norov
translatio
translated
major str
2.1.2 L
 A
below. 
1). Noro
“anchor”
2). Norov
F
to right, Nor
ite, the cryst
n. 90 
he noroviru
rom 7.3 to 7
irus, ORF 
nally cleave
 to the maj
ucture of no
ife Cycle of
 number of 
virus attach
 itself on the
irus entry to
igure 2.3 Th
oviruses elec
al structure o
s genome is
.5kb. It is o
1 will be
d to release
or capsid p
rovirus. 
 Norovirus 
steps are in
 to the spe
 host cell su
 the hose ce
e structure 
tron microsco
f the HBGA
 a single str
rganized in
 translated 
 at least six 
rotein. This
volved in no
cific carboh
rface.  
ll and relea
of norovirus
py, a single 
 binding inte
ain, positive
to three con
to a large
mature nons
genome is 
rovirus life
ydrate whi
se the genom
es at differe
virus like par
rface. Figur
 sense RNA
served ORF
 polyprotei
tructural pro
packaged b
 cycle. The 
ch located 
ic material
nt levels 
ticle, the P d
e is taken fr
 molecule 
s as shown 
n, which i
teins. ORF
y capsid pro
different ste
on the hos
.  
imer with HB
om publisher
which rangi
in figure 2.2
s co- and 
 2 and ORF 
tein to form
ps are desc
t cell surfa
108 
 
GAs 
 with 
ng in 
.  In 
post- 
3 are 
 the 
ribed 
ce to 
 109 
 
3). The viral genome is translated through interactions with VPg at the 5’ end of the genome. 
4). The ORF1 polyprotein is cleaved and the replication complex is generated.  
5). Genome replication was achieved by RNA replication.  
6). The replicated genomes are translated and finally packaged into the virus capsid.  
7). Virion assembly and virus exit from the host cell. 
2.1.3 Norovirus binding and entry to the host cell 
 The initial stage of norovirus life cycle is the virus binds with the host cell. This process 
is known to involve carbohydrates which are located on the host cell surface. HBGAs have been 
shown to bind with norovirus via capsid protein - carbohydrate intersection.91 Protruding (P) 
domain of the capsid protein is responsible for the recognition in the norovirus and host cell 
binding process. Structure of the P domain complexed with A type HBGA and H type HBGA is 
shown in figure 2.4. 
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Figure 2.4 Norovirus P domain- HBGAs interactions. 
a) The electron density of the bound penta-saccharide. b) The binding site of P domain. c) and d). The 
hydrogen bond interactions in the P domain binding site. Figure is taken from publisher89 with 
permission.  
 
 The HBGA binding site in GI strains is very different from that in GII strains (Figure 2.5). 
Although the genotype sequence of GI and GII is different, the P dimer are similar organized, the 
carbohydrate binding site in GII and GI is distinctly different, not only different in its location, 
but also in its structural characteristics.  Although some studies have been performed to elucidate 
the binding preferences of some VLPs, several questions are still unanswered. For example, most 
of the binding studies have used glycopolymers, which were not chemically well defined. 
Second, most of the studies were performed using VLPs and not intact viruses. Thus, the binding 
preferences are not very clear. We have attempted to study the binding preferences using glycan 
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microarrays and SPR in an attempt to develop glycan based tests for norovirus. These studies are 
described below.  
 
Figure 2.5 Different locations of the HBGAs binding sites in GI (red circle) and GII (blue circle). 
Relative locations of the HBGA biding sites in GI (red circle) and GII (blue circle) in P dimer. 
Figure is taken from publisher with permission. 89 
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1. A library of Histo blood group antigens and Lewis antigens have been synthesized and 
attached on BSA via the amine groups of the lysine side chain. Approximately 30 units of 
glycan units have been attached to a single molecule of BSA. 
2. A focused glycan array of 31 HBGAs and LAs were printed on the surface of array slide 
which modified with NHS active ester, after incubation, glycans could be anchored on 
the surface by forming covalent bond between NHS active ester and amine of BSA. 
3. Ethanol amine is used to cover the unprinted area to block unreacted NHS esters. 
4. The array slide is incubated with different strains of norovirus or VLP. Nonspecific 
binding is washed away by DI water and PBS buffer. 
5. The array slide is incubated with primary antibody, followed by extensive washing using  
DI water and PBS buffer to remove unbound antibody 
6. The array slide is incubated with secondary antibody bearing fluorescent tag, followed by 
extensive washing using DI water and PBS buffer to removed unbound secondary 
antibody. 
7. The slide is scanned by microarray scanner to generate the binding image. 
8. The image is analyzed by image analyzer software, and the binding pattern is given as a 
graph format. 
 
 In this chapter, a panel of Histo Blood Group Antigens (HBGAs) and Lewis antigens 
(LA) has been used to capture norovirus. The HBGAs were developed and tested with different 
strains of norovirus and VLP using glycan microarrays.  A glycan array of 31 glycans with 
different HBGA/LA glycans were printed onto a surface modified slide to generate a small 
focused microarray. The binding of different virus like particles (VLPs) including GI1, GII4 and 
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SMV and their corresponding intact viruses obtained from human challenge studies were 
evaluated using the glycan microarrays. We found that unique binding patterns for the different 
VLPs were obtained suggesting that a "fingerprint" pattern of recognition could be obtained for 
each strain. However, the binding patterns of the intact viruses did not match the binding patterns 
for the corresponding VLPs, indicating that matrix issues or antibodies may be affecting the 
binding when intact viruses were used. Since the virus cannot be grown in a laboratory 
environment, the antibodies are generated using VLPs, therefore, the antibodies for the VLPs 
may be different than that observed for the intact virus. To understand these differences, we 
developed biotinylated H type glycans and these glycans were tested using SPR (Surface 
Plasmon Resonance). We found that the different H type glycans give rise to differential binding, 
suggesting that the matrix may be interfering with the binding of intact viruses. These results are 
presented in this chapter. 
 The chemical structures of the 31 glcyans are given in figure 2.7 and the Symbols 
represent the structures are given in figure 2.8. These glycans were synthesized by members of 
Professor Todd Lowary's group, Alberta, Canada. The synthesis of the glycans has been 
published. 92 
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Globotriose-HSA (3 atom spacer)V7
Lacto-N-fucopentaose I-BSA (LNFP I-BSA) (3 atom spacer)V8
6-Sulpho Lewisx-BSA (3 atom spacer)V9
6-Sulpho Lewisa-BSA (3 atom spacer)V10
Lacto-N-fucopentaose II-BSA (LNFP II-BSA) (3 atom spacer)V11
Lacto-N-difucohexaose I-BSA (LNDFH I-BSA) (3 atom spacer)V12
3-Sulpho Lewisa-BSA (3 atom spacer)V13
O-(2-Aminoethyl) polyethylene glycol 3000PEG
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Figure 2.7 Structures of 31 unique histoblood group antigens 
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was measured by the Genepix scanner using mouse (or rabbit) sera to the respective strain and anti-mouse 
or anti rabbit rhodamine labeled antibody was scanned at 532nm.  The experiments were performed in 
duplicate. 
 
 The SMV VLP shows high binding affinity with H5, V3, and V7 glycans in three 
different concentrations. The fluorescent intensity was not decreased when the VLP 
concentration was reduced. This indicates that SMV VLP have strong binding affinity with H5, 
V3 and V7. All of Blood Group Antigens A types shows binding with SMV VLP. But the 
fluorescent intensity was decreased when the concentration was reduced. This indicates that the 
A type antigen can bind with SMV VLP, but the binding affinity is weak, once the VLP 
concentration decreased, the glycan cannot capture enough VLP to represent the fluorescent 
signal.  
 GI.1 shows the binding affinity with the entire glycan library except the negative control, 
however, the binding is weak except V8. GII.4 shows strong binding with V7 and weak binding 
with V8. 
2.2.2 Microarray results with virus from stool suspensions 
 We performed the same assays with the actual viruses, namely GI.1. Norwalk, GII.2 
Snow Mountain (SMV) and GII.4 New Orleans strains obtained from human challenge studies 
The results are shown in Figure 2.12-2.14. Our first studies were with SMV viruses and it was 
gratifying to observe that the binding pattern for the virus mirrors that of the SMV VLPs. We 
tested at different concentrations and found that glycans capture the virus at very low titers. We 
also found that stool samples without SMV virus did not bind to any of the glycans, which was 
as expected.  
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by Genepix scanner at 532 nm. Rignt: Fluorescence image of Stool supernatant with no virus. As 
expected, there was no nonspecific binding. 
 
 Testing with Norwalk virus and the NO strains was also performed. Unlike the SMV 
strain, the Norwalk and NO virus strains did not behave like their respective VLPs, the patterns 
were very different. We tested these strains with antibodies from different sources and the results 
varied depending on the source of the VLPs used to generate the antibodies.  
2.2.3 Summary of the glycan microarray results 
 A library of synthetic analogs of Histo Blood Group Antigens conjugated to BSA was 
printed onto commercial glass slides. VLPs and intact virus samples were screened for binding 
using the focused microarrays. The binding patterns for the VLP’s (GI.1 Norwalk, GII.2 Snow 
Mountain and GII.4 New Orleans) are very different and unique. This indicates that a pattern of 
recognition could be used to type each strain. We also performed the same assays with intact 
virus. The SMV virus shows same binding pattern with SMV VLP. The stool sample without 
SMV shows no binding with any glycans. The binding of GI.1 and GII.4 shows very different 
pattern with VLPs. We tested these strains with antibodies from different sources and the results 
varied depending on the source of the VLPs used to generate the antibodies. Antibodies 
generated against VLPs may not recognize the actual virus, which could be one of the reasons 
why antibody based lateral flow assays are not highly sensitive and/or selective. Our approach to 
overcome this problem is using synthetic glycans as reporters because noroviruses have multiple 
protein receptors that bind to HBGA glycans and therefore, one can envision capture and report 
with glycans. While we obtained excellent results for one strain, the binding pattern for two other 
strains did not match the binding pattern of the respective VLPs. There could be a number of 
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reasons for these differences. First, antibodies generated using VLPs may not recognize the intact 
virus. Second, soluble glycans may be present in stool samples that inhibit the binding of the 
virus to the glycan microarray. Third, the sample preparation process may result in result in virus 
destruction. In the next section, we used a non-labeling technique i.e. SPR (Surface Plasmon 
Resonance) to ascertain if antibodies were the issue or matrix issues contributed to the 
differences between VLPs and viruses.  
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2.3.2 Results and Discussion 
 The streptavidin coated Biacore microfluidics sensor chip SA was prepared following 
manufacturer protocols. Briefly,four biotinylated ligands (H type I, II, III and the biotinylated 
PEG) were coated onto four channels of a streptavidin coated biosensor chip as different ligand 
densities. Next, VLPs from different strains were introduced onto the sensor to determine the 
relative binding affinities.  
 
Figure 2.17 Example of a sensogram to determine relative binding affinities of the glycans. 
Two different VLPs, G1.1 and GII.4 were used in these sets of experiments and the sensor surface had a 
high density of ligands. SPR binding is expressed in response unit (RU). The chemical structures of 
HBGAs immobilized on the SPR surfaces are indicated. 
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 For the initial test, we immobilized H type I, H type II and H type III at 10ug/ml for 7 
mins with the flow rate of 10 μl/min. The glycans have been successfully immobilized on the 
sensor chip SA, and gives an increase in relative refraction units (RU) of 800.3 (H type I), 759.9 
(H type II), and 630.8(H type III), respectively. Surface performance test indicates that the 
glycan is stable and couldn’t be removed by the PBS buffer flow. 10μg/ml of GI.1 VLPs or GII.4 
VLPs was injected over the sensor chip SA at the flow rate of 5 μl/min for 20 min. The binding 
was monitored as increasing relative RU.  The result shows that GI.1 VLPs has strong binding 
affinity with H type I which gives the increased RU of 1177.1. H type II and H type III shows 
weak binding affinity and gives the increased RU of 128.5 and 455.9, respectively. This 
indicated that H type I could be used to capture GI.1 VLPs. The GII.4 shows higher binding 
affinity compare to GI.1 VLPs with those glycans as shown in figure 2.19. H type I shows the 
highest binding and gives the increased RU as 4935.4, H type II and H type III gives the 
increased RU of 1548.8 and 3891.1 respectively. Taken together, H type I is a suitable glycan to 
capture GI.1 and GII.4 VLPs. It is also clear from the sensograms that GII.4 binds with a higher 
affinity to the glycans than G1.1. We tried to regenerate the sensor chipsusing a variety of 
conditions to obtain binding affinity constants. Unfortunately, we were unsuccessful in removing 
the VLPs without destroying the glycan coated surface, which indicates that the binding is very 
strong.  
 Therefore, we decided to reduce the glycan density (Figure 2.20). When the ligand 
densities are high, the VLPs bound extremely tightly. In contrast, when the ligand density is 
reduced, the VLPs do not bind tightly and therefore we can regenerate the surface. To 
successfully regenerate the glycan surface of sensor chips, we decreased the contact time of 
immobilization process. 10μg/ml glycans is immobilized for 30s with the flow rate of 10 μl/min 
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2.3.3 Summary and Future Work 
 In this chapter, we developed a focused microarray for the detection of norovirus strains. 
We envisioned a "fingerprint" pattern for each strain. This strategy works well when VLPs are 
tested.  However, when viruses are tested, matrix effects play a major role. Unfortunately,  the 
virus cannot be cultivated in vitro, which poses problems for the study of this virus as we have to 
rely on human  challenge studies for obtaining the virus, which is obtained as a stool suspension. 
We are currently exploring other methods to detect this virus.  
2.3.4 Experiment section 
2.3.4.1 Immobilization of Glycans 
 Synthetic glycans were covalently immobilized onto Nexterion® NHS slides using 
DIGILAB Omnigrid Micro printer in 300 mM phosphate buffer with 0.005% Tween-20 at pH 
8.5. Each glycan was printed twenty times in quintuplicate at 200 µM concentration.  Following 
printing, the glycans were allowed to react for 30 min at 60% humidity. After overnight 
desiccation, the slides were blocked for 60 min with 50 mM ethanolamine in 50 mM boric acid 
buffer (pH 9.5), washed 3 times with deionized (DI) water, dried and stored at -20°C. 
2.3.4.2 Virus Binding Assay 
 To determine binding pattern of detection, a serial double fold dilution was performed for 
SMV VLP. GI.1 and GII.4 were tested with a constant concentration (10μg/ml). The 
concentration of SMV VLP was tested from 10μg/ml. Each concentration of virus was applied to 
the microarray for 60 min in a buffer consisting of PBS and 0.05% Tween-20. Post-virus 
incubation and wash (three times with PBS and 0.05% Tween-20 and two times with PBS), 
antibodies specific to each virus were diluted and added to the microarray for 60 min. Slides 
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were washed as previously described above and incubated for 60 min with the appropriate 
fluorescently tagged secondary antibodies. The slides were washed as described above, followed 
by a DI water rinse. The slides were dried and scanned using the GenePix®4000B scanner. All 
experiments were performed in triplicate. 
2.3.4.3 SPR studies 
  Binding of VLPs to biotinylated glcyans was measured using a BIACORE T200 
instrument (GE Healthcare). Biotinylated glycoconjugates were injected over streptavidin-coated 
SA sensor chips (GE Healthcare) at 10 μL min−1. A reference flow cell was used to record the 
background response, and background was subtracted from each sample. Biotinylated PEG was 
used as the reference. The running buffer used in all experiments was PBS buffer (pH 7.4). All 
SPR experiments were performed at room temperature. VLPs were injected over the chip at 5 μL 
min−1 for 20 min. Binding was detected as a change in the refractive index at the surface of the 
chip as measured by response units (RU). Data analysis was carried out using BIA evaluation 3.0 
software. 
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